<?xml version="1.0"  ?><!DOCTYPE pmc-articleset PUBLIC "-//NLM//DTD ARTICLE SET 2.0//EN" "https://dtd.nlm.nih.gov/ncbi/pmc/articleset/nlm-articleset-2.0.dtd"><pmc-articleset><article xmlns:mml="http://www.w3.org/1998/Math/MathML" xmlns:ali="http://www.niso.org/schemas/ali/1.0/" xml:lang="en" article-type="research-article" dtd-version="1.4"><processing-meta base-tagset="archiving" mathml-version="3.0" table-model="xhtml" tagset-family="jats"><restricted-by>pmc</restricted-by></processing-meta><front><journal-meta><journal-id journal-id-type="nlm-ta">Biochem J</journal-id><journal-id journal-id-type="iso-abbrev">Biochem J</journal-id><journal-id journal-id-type="pmc-domain-id">671</journal-id><journal-id journal-id-type="pmc-domain">portlandopen</journal-id><journal-id journal-id-type="publisher-id">bcj</journal-id><journal-title-group><journal-title>Biochemical Journal</journal-title></journal-title-group><issn pub-type="ppub">0264-6021</issn><issn pub-type="epub">1470-8728</issn><custom-meta-group><custom-meta><meta-name>pmc-is-collection-domain</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-collection-title</meta-name><meta-value>Portland Press Open Access</meta-value></custom-meta></custom-meta-group></journal-meta><article-meta><article-id pub-id-type="pmcid">PMC12751073</article-id><article-id pub-id-type="pmcid-ver">PMC12751073.1</article-id><article-id pub-id-type="pmcaid">12751073</article-id><article-id pub-id-type="pmcaiid">12751073</article-id><article-id pub-id-type="pmid">41003242</article-id><article-id pub-id-type="doi">10.1042/BCJ20253431</article-id><article-id pub-id-type="publisher-id">BCJ-2025-3431</article-id><article-version article-version-type="pmc-version">1</article-version><article-categories><subj-group subj-group-type="heading"><subject>Research Article</subject></subj-group><subj-group subj-group-type="heading"><subject>Enzymology</subject></subj-group><subj-group subj-group-type="heading"><subject>Molecular Interactions</subject></subj-group><subj-group subj-group-type="heading"><subject>Signaling</subject></subj-group></article-categories><title-group><article-title>Unconventional binding of calmodulin to CHK2 kinase inhibits catalytic activity</article-title></title-group><contrib-group><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-1318-514X</contrib-id><name name-style="western"><surname>Horne</surname><given-names initials="CR">Christopher R.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp"/><role vocab-term="Conceptualization" vocab-term-identifier="https://credit.niso.org/contributor-roles/conceptualization/" vocab="credit" vocab-identifier="https://credit.niso.org/">Conceptualization</role><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><role vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/" vocab="credit" vocab-identifier="https://credit.niso.org/">Methodology</role><role vocab-term="Writing &#x2013; original draft" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-original-draft/" vocab="credit" vocab-identifier="https://credit.niso.org/">Writing &#8211; original draft</role><email>horne.c@wehi.edu.au</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Wang</surname><given-names initials="T">Tingting</given-names></name><xref rid="aff4" ref-type="aff">4</xref><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><role vocab-term="Methodology" vocab-term-identifier="https://credit.niso.org/contributor-roles/methodology/" vocab="credit" vocab-identifier="https://credit.niso.org/">Methodology</role><email>tingting.wang@flinders.edu.au</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Young</surname><given-names initials="SN">Samuel N.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><email>syoung@wehi.edu.au</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dite</surname><given-names initials="TA">Toby A.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><email>dite.t@wehi.edu.au</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Nyvall</surname><given-names initials="HG">Hunter G.</given-names></name><xref rid="aff5" ref-type="aff">5</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><email>hnyvall@uvic.ca</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Suresh</surname><given-names initials="S">Sushant</given-names></name><xref rid="aff5" ref-type="aff">5</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><email>sushantsuresh@uvic.ca</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Davies</surname><given-names initials="KA">Katherine A.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><email>davies.k@wehi.edu.au</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Gonzalez Castro</surname><given-names initials="A">Abner</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><email>gonzalezcastro.a@wehi.edu.au</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Vaibhav</surname><given-names initials="V">Vineet</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><email>vaibhav.v@wehi.edu.au</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Mather</surname><given-names initials="LJ">Lucy J.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><email>mather.l@wehi.edu.au</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Dagley</surname><given-names initials="LF">Laura F.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><email>dagley.l@wehi.edu.au</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Belousoff</surname><given-names initials="MJ">Matthew J.</given-names></name><xref rid="aff3" ref-type="aff">3</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><email>matthew.belousoff@monash.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Manning</surname><given-names initials="G">Gerard</given-names></name><xref rid="aff6" ref-type="aff">6</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><email>manning@manninglab.org</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Means</surname><given-names initials="AR">Anthony R.</given-names></name><xref rid="aff7" ref-type="aff">7</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><email>armeans@bcm.edu</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Burke</surname><given-names initials="JE">John E.</given-names></name><xref rid="aff5" ref-type="aff">5</xref><xref rid="aff8" ref-type="aff">8</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><email>jeburke@uvic.ca</email></contrib><contrib contrib-type="author"><name name-style="western"><surname>Petersen</surname><given-names initials="J">Janni</given-names></name><xref rid="aff4" ref-type="aff">4</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><email>janni.petersen@flinders.edu.au</email></contrib><contrib contrib-type="author" corresp="yes" equal-contrib="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0002-1896-9798</contrib-id><name name-style="western"><surname>Scott</surname><given-names initials="JW">John W.</given-names></name><xref rid="aff3" ref-type="aff">3</xref><xref rid="aff9" ref-type="aff">9</xref><xref rid="aff10" ref-type="aff">10</xref><xref rid="cor1" ref-type="corresp"/><xref rid="an1" ref-type="author-notes">*</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><role vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/" vocab="credit" vocab-identifier="https://credit.niso.org/">Supervision</role><email>john.scott@monash.edu</email></contrib><contrib contrib-type="author" corresp="yes"><contrib-id contrib-id-type="orcid" authenticated="false">https://orcid.org/0000-0003-0195-3949</contrib-id><name name-style="western"><surname>Murphy</surname><given-names initials="JM">James M.</given-names></name><xref rid="aff1" ref-type="aff">1</xref><xref rid="aff2" ref-type="aff">2</xref><xref rid="aff3" ref-type="aff">3</xref><xref rid="cor1" ref-type="corresp"/><xref rid="an1" ref-type="author-notes">*</xref><role vocab-term="Formal Analysis" vocab-term-identifier="https://credit.niso.org/contributor-roles/formal-analysis/" vocab="credit" vocab-identifier="https://credit.niso.org/">Formal Analysis</role><role vocab-term="Investigation" vocab-term-identifier="https://credit.niso.org/contributor-roles/investigation/" vocab="credit" vocab-identifier="https://credit.niso.org/">Investigation</role><role vocab-term="Project administration" vocab-term-identifier="https://credit.niso.org/contributor-roles/project-administration/" vocab="credit" vocab-identifier="https://credit.niso.org/">Project administration</role><role vocab-term="Supervision" vocab-term-identifier="https://credit.niso.org/contributor-roles/supervision/" vocab="credit" vocab-identifier="https://credit.niso.org/">Supervision</role><role vocab-term="Writing &#x2013; review &amp; editing" vocab-term-identifier="https://credit.niso.org/contributor-roles/writing-review-editing/" vocab="credit" vocab-identifier="https://credit.niso.org/">Writing &#8211; review &amp; editing</role><email>jamesm@wehi.edu.au</email></contrib></contrib-group><aff id="aff1">
<label>1</label>Walter and Eliza Hall Institute of Medical Research, 1G Royal Parade, Parkville, Victoria, 3052, Australia</aff><aff id="aff2">
<label>2</label>Department of Medical Biology, University of Melbourne, Parkville, Victoria, 3052, Australia</aff><aff id="aff3">
<label>3</label>Drug Discovery Biology, Monash Institute of Pharmaceutical Sciences, Monash University, Victoria, 3052, Australia</aff><aff id="aff4">
<label>4</label>College of Medicine and Public Health, Flinders University, Adelaide, South Australia, 5001, Australia</aff><aff id="aff5">
<label>5</label>Department of Biochemistry and Microbiology, University of Victoria, Victoria, BC, Canada</aff><aff id="aff6">
<label>6</label>NuaBio Research, Burlingame, 94010, CA, U.S.A.</aff><aff id="aff7">
<label>7</label>Molecular and Cellular Biology, Baylor College of Medicine, Houston, TX, 77030, U.S.A.</aff><aff id="aff8">
<label>8</label>Department of Biochemistry and Molecular Biology, University of British Columbia, Vancouver, BC, Canada</aff><aff id="aff9">
<label>9</label>The Florey Institute of Neuroscience and Mental Health, Parkville, Victoria, 3052, Australia</aff><aff id="aff10">
<label>10</label>St Vincent&#8217;s Institute of Medical Research, Fitzroy, Victoria, 3065, Australia</aff><author-notes><corresp id="cor1"><bold>Correspondence:</bold> Christopher R. Horne (<email>horne.c@wehi.edu.au</email>), John W. Scott (<email>john.scott@monash.edu</email>) and James M. Murphy (<email>jamesm@wehi.edu.au</email>)</corresp><fn fn-type="equal" id="an1"><p>*These authors contributed equally to this work.</p></fn></author-notes><pub-date pub-type="collection"><day>05</day><month>12</month><year>2025</year></pub-date><pub-date pub-type="epub"><day>03</day><month>12</month><year>2025</year></pub-date><volume>482</volume><issue>23</issue><issue-id pub-id-type="pmc-issue-id">503396</issue-id><fpage>1759</fpage><lpage>1777</lpage><history><date date-type="received"><day>07</day><month>9</month><year>2025</year></date><date date-type="rev-recd"><day>17</day><month>9</month><year>2025</year></date></history><pub-history><event event-type="pmc-release"><date><day>03</day><month>12</month><year>2025</year></date></event><event event-type="pmc-live"><date><day>31</day><month>12</month><year>2025</year></date></event><event event-type="pmc-last-change"><date iso-8601-date="2025-12-31 10:25:12.790"><day>31</day><month>12</month><year>2025</year></date></event></pub-history><permissions><copyright-statement>&#169; 2025 The Author(s).</copyright-statement><copyright-year>2025</copyright-year><license><ali:license_ref specific-use="textmining" content-type="ccbylicense">https://creativecommons.org/licenses/by/4.0/</ali:license_ref><license-p>This is an open access article published by Portland Press Limited on behalf of the Biochemical Society and distributed under the <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="uri" xlink:href="https://creativecommons.org/licenses/by/4.0/">Creative Commons Attribution License 4.0 (CC BY)</ext-link>.</license-p></license></permissions><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" content-type="pmc-pdf" xlink:href="bcj-482-23-BCJ20253431.pdf"/><self-uri xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bcj-482-23-BCJ20253431.pdf"/><abstract><p>Calmodulin (CaM) serves an essential role in eukaryotic cells as a Ca<sup>2+</sup> sensor. Ca<sup>2+</sup> binding leads to conformation changes in CaM that enable engagement of a repertoire of enzymes and the regulation of their catalytic activities. Classically, Ca<sup>2+</sup>-CaM binds to an inhibitory pseudosubstrate sequence C-terminal to the kinase domain in members of the Ca<sup>2+</sup>-CaM-dependent protein kinase (CAMK) family and relieves inhibition to promote catalytic activity. Here, we report an unexpected mechanism by which CaM can bind CHK2 kinase to inhibit its kinase activity. Using biochemical, biophysical and structural mass spectrometry, we identify a direct interaction of Ca<sup>2+</sup>-CaM with the CHK2 kinase domain that suppresses CHK2 catalytic activity <italic toggle="yes">in vitro</italic> and identify K373 in CHK2 as crucial for cell proliferation in human cells following DNA damage. Our findings add direct suppression of kinase activity to the repertoire of CaM&#8217;s functions, complementing the paradigmatic mechanism of promoting kinase activity through autoinhibitory domain sequestration.</p></abstract><kwd-group kwd-group-type="author"><kwd>allosteric regulation</kwd><kwd>calmodulin</kwd><kwd>calcium signalling</kwd><kwd>cell cycle</kwd><kwd>kinases</kwd></kwd-group><custom-meta-group><custom-meta><meta-name>pmc-status-qastatus</meta-name><meta-value>0</meta-value></custom-meta><custom-meta><meta-name>pmc-status-live</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-status-embargo</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-status-released</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-open-access</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-olf</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-manuscript</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-legally-suppressed</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-pdf</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-has-supplement</meta-name><meta-value>yes</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-pdf-only</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-suppress-copyright</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-real-version</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-is-scanned-article</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-preprint</meta-name><meta-value>no</meta-value></custom-meta><custom-meta><meta-name>pmc-prop-in-epmc</meta-name><meta-value>yes</meta-value></custom-meta></custom-meta-group></article-meta></front><body><sec sec-type="intro" id="s1"><title>Introduction</title><p>Calmodulin (CaM) is a ubiquitous intracellular protein in eukaryotic cells, which constitutes up to 0.1% of the total proteome and serves a crucial function as a Ca<sup>2+</sup> sensor [<xref rid="BCJ-2025-3431C1" ref-type="bibr">1</xref>]. Ca<sup>2+</sup> is a crucial second messenger in many facets of biology, from muscle contractility to neuronal communication, and its binding to CaM has been likened to a ligand binding to and activating a receptor [<xref rid="BCJ-2025-3431C1" ref-type="bibr">1</xref>,<xref rid="BCJ-2025-3431C2" ref-type="bibr">2</xref>]. CaM binding to four Ca<sup>2+</sup> ions promotes a conformational change that enables engagement of downstream signalling effectors [<xref rid="BCJ-2025-3431C3" ref-type="bibr">3</xref>,<xref rid="BCJ-2025-3431C4" ref-type="bibr">4</xref>], including GTPases, GPCRs, adenylyl cyclases, pseudokinases, phosphatases, lipid and protein kinases [<xref rid="BCJ-2025-3431C5" ref-type="bibr">5</xref>], to modulate their activities. The cellular functions of these target proteins can be regulated by CaM via a range of mechanisms, such as by CaM dictating their localisation within cells, the occlusion of substrate or partner protein binding, or by modulating a binding partner&#8217;s catalytic activity.</p><p>CaM is composed of two globular Ca<sup>2+</sup>-binding domains separated by a solvent-exposed central helix [<xref rid="BCJ-2025-3431C1" ref-type="bibr">1</xref>]. Each globular domain contains two EF-hand Ca<sup>2+</sup>-binding motifs that bind Ca<sup>2+</sup> with low micromolar affinity. The CaM-binding sequences of the target proteins each contain 15&#8211;30 amino acids [<xref rid="BCJ-2025-3431C3" ref-type="bibr">3</xref>,<xref rid="BCJ-2025-3431C4" ref-type="bibr">4</xref>] and bind CaM with affinities ranging from low nanomolar to low micromolar [<xref rid="BCJ-2025-3431C6" ref-type="bibr">6</xref>,<xref rid="BCJ-2025-3431C7" ref-type="bibr">7</xref>]. While the precise target sequence is highly variable among the plethora of interactors, there are two common principles guiding CaM binding. First, the CaM-binding sequence contains a cluster of two to three basic residues, which defines the polarity of the binding of the sequence to CaM. Second, the CaM-binding sequence typically forms a helix and projects hydrophobic anchor residues into non-polar clefts within CaM (reviewed in ref. [<xref rid="BCJ-2025-3431C1" ref-type="bibr">1</xref>,<xref rid="BCJ-2025-3431C5" ref-type="bibr">5</xref>,<xref rid="BCJ-2025-3431C8" ref-type="bibr">8</xref>]). Structural studies have revealed enormous diversity in the mode of interaction for CaM-binding sequences, where the periodicity of the helix allows the anchor residues to occur in diverse positions. Accordingly, anchor residue positions of 1; 4 or 5; 8 or 10; 13, 14, 16 or 17 have been identified in a variety of CaM-binding sequences, often with anchor residues contributed beyond the helix [<xref rid="BCJ-2025-3431C5" ref-type="bibr">5</xref>]. Our current understanding allows for predictions of conventional CaM-binding sequences, although prediction of non-canonical CaM-binding sequences remains elusive and relies on experimental determination.</p><p>Ca<sup>2+</sup>-CaM serves a crucial function in the activation of the Ca<sup>2+</sup>-CaM-dependent protein kinase (CAMK) family following Ca<sup>2+</sup> influx into cells [<xref rid="BCJ-2025-3431C2" ref-type="bibr">2</xref>]. The CAMK family is a large and diverse kinase subfamily, which totals 74 family members [<xref rid="BCJ-2025-3431C9" ref-type="bibr">9</xref>]. Among these, the activation of myosin light chain kinase (MLCK), and CAMK1 (including CaMKI and CaMKIV kinases) and CAMK2 (including CaMKII kinases) families are known to occur via a two-step Ca<sup>2+</sup>-CaM-dependent process, although if and how Ca<sup>2+</sup>-CaM activates other CAMK kinases is poorly understood. In the canonical mechanism, Ca<sup>2+</sup>-CaM binds to a sequence C-terminal to the kinase domains, which overlaps an autoinhibitory sequence that occludes the active site. Ca<sup>2+</sup>-CaM binding displaces the autoinhibitory sequence from the active site, thereby activating the kinase. The mechanism is best described for CaMKII [<xref rid="BCJ-2025-3431C10" ref-type="bibr">10</xref>], which, along with DAPK1 [<xref rid="BCJ-2025-3431C11" ref-type="bibr">11</xref>], DAPK2 [<xref rid="BCJ-2025-3431C12" ref-type="bibr">12</xref>] and GRK5 [<xref rid="BCJ-2025-3431C13" ref-type="bibr">13</xref>], are the only four structures of Ca<sup>2+</sup>-CaM bound kinase structures reported thus far. The CaMKII autoinhibitory sequence binds in a helical conformation to the kinase domain C-lobe to prevent CaMKII activation by trans-autophosphorylation. Ca<sup>2+</sup>-CaM binds to a sequence overlapping the C-terminal autoinhibitory sequence, leading to unfolding of the N-terminus of the autoinhibitory helix and formation of an extended helix that then binds CaM [<xref rid="BCJ-2025-3431C10" ref-type="bibr">10</xref>]. CaM binding thus induces dissociation of the autoinhibitory sequence from the CaMKII kinase domain C-lobe, which in turn allows activation via autophosphorylation to ensue [<xref rid="BCJ-2025-3431C14" ref-type="bibr">14</xref>]. Similarly, in the case of CAMK1 family kinases, their upstream activating kinases, the CaMKKs, are able to access and phosphorylate the CaMK activation loops to activate their kinase activity when the autoinhibitory sequence is sequestered by Ca<sup>2+</sup>-CaM [<xref rid="BCJ-2025-3431C2" ref-type="bibr">2</xref>]. That Ca<sup>2+</sup>-CaM activates both CAMK and CAMKK kinases is intriguing and indicates a crucial function for Ca<sup>2+</sup>-CaM in signal fidelity and amplification upon pathway engagement. Based on limited structural data and extensive biochemical studies, the CaM-binding sequence C-terminal to the kinase domain is the target of Ca<sup>2+</sup>-CaM in both the CaMK and CaMKK kinases and has served as a paradigm for how CaM can promote kinase catalytic activity for decades. However, recent studies indicate that kinase domains themselves can directly bind and be regulated by CaM, as exemplified by PSKH1 kinase [<xref rid="BCJ-2025-3431C15" ref-type="bibr">15</xref>]. Whether others among the vast array of CAMK kinases, and kinases from other families, are Ca<sup>2+</sup>-CaM regulated, and the underlying mechanisms of regulation, remain to be established.</p><p>A member of the CAMK group &#8211; Checkpoint kinase 2 (CHK2 or CHEK2) &#8211; is a highly studied protein kinase owing to its essential role in regulating cell cycle progression following DNA damage [<xref rid="BCJ-2025-3431C16" ref-type="bibr">16</xref>]. CHK2 is a multidomain protein comprising an N-terminal SQ/TQ cluster domain (SCD), a Forkhead-associated (FHA) domain and a C-terminal Ser/Thr kinase domain. Following DNA damage, the upstream kinase, ATM, phosphorylates Thr68 within the CHK2 SCD, which introduces a site for CHK2 FHA domain binding [<xref rid="BCJ-2025-3431C17" ref-type="bibr">17</xref>,<xref rid="BCJ-2025-3431C18" ref-type="bibr">18</xref>]. CHK2 is reported to form a transient homodimer, presumably mediated by FHA domain binding to pT68 <italic toggle="yes">in trans</italic> [<xref rid="BCJ-2025-3431C19" ref-type="bibr">19</xref>]<italic toggle="yes">,</italic> which in turn leads to CHK2 activation loop phosphorylation on T383 and elevated kinase activity [<xref rid="BCJ-2025-3431C20" ref-type="bibr">20</xref>]. CHK2 does not harbour a canonical autoinhibitory Ca<sup>2+</sup>-CaM-binding sequence yet was previously proposed to be activated by Ca<sup>2+</sup>-CaM [<xref rid="BCJ-2025-3431C21" ref-type="bibr">21</xref>], although these data were far from conclusive. Here, we identify an unexpected role for Ca<sup>2+</sup>-CaM as an inhibitor of CHK2 kinase activity that functions via direct engagement of the CHK2 kinase domain. Structural mass spectrometry, modelling and mutational studies pinpoint a bidentate interaction of the two EF-hand domains of CaM with the N- and C-lobes of CHK2, centred on the catalytic loop. Moreover, disruption of the CaM-binding interface via CRISPR mutation of the critical residue in CHK2, K373, impeded cell proliferation and ablated proliferation following DNA damage in human cells. This functionally crucial lysine is highly conserved among orthologs, which suggests an ancestral function for CaM as the sensor of Ca<sup>2+</sup> flux that attenuates CHK2 activity and cell proliferation. These findings expand the repertoire of mechanisms by which CaM can regulate the catalytic activity of protein kinases, raising the prospect that CaM may function allosterically to modulate the activities of enzyme targets more broadly in nature.</p></sec><sec sec-type="results" id="s2"><title>Results</title><sec id="s2-1"><title>Ca<sup>2+</sup>-CaM directly binds and inhibits CHK2 catalytic activity</title><p>Upon Ca<sup>2+</sup> binding, CaM typically binds to an autoinhibitory site C-terminal to the kinase domain in CAMK family kinases to promote catalytic activity (<xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1A</xref>). A control CAMK family kinase, CaMKK2, which is reported to contain a conventional CaM-binding sequence that is autoinhibitory [<xref rid="BCJ-2025-3431C22" ref-type="bibr">22</xref>] (<xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1A</xref>), bound CaM in a Ca<sup>2+</sup>-dependent manner by Far Western assay (<xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1B</xref>). Surprisingly, like CaMKK2, immobilised CHK2 similarly bound CaM in a Ca<sup>2+</sup>-dependent manner that was compromised by the Ca<sup>2+</sup> chelator, EGTA (<xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1B</xref>). CHK2 lacks a predicted CaM-binding sequence, indicating that CaM engages CHK2 via an unconventional binding mode. However, the observed CaM binding to CHK2 is not non-specific because no signal was detected for the non-CaMK family kinome member, MLKL (<xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1B</xref>).</p><fig position="float" id="BCJ-2025-3431F1" fig-type="figure" orientation="portrait"><label>Figure 1</label><caption><title>Ca<sup>2+</sup>-CaM interacts with human CHK2 to inhibit kinase activity via interaction with the kinase domain.</title><p>
<bold>(A</bold>) Schematic of the conventional mode of Ca<sup>2+</sup>-CaM activation in members of the Ca<sup>2+</sup>-CaM-dependent protein kinase (CaMK) family. Upon Ca<sup>2+</sup> influx, Ca<sup>2+</sup>-CaM binds a linear sequence (CaM-binding sequence; CaMBS; orange) that is proximal to the CaMK kinase domain (blue). This interaction restores activity by sequestering an autoinhibitory pseudosubstrate sequence, which formerly obstructed the active site. (<bold>B</bold>) Far Western blots show that recombinant full-length CHK2 and positive control kinase, CaMKK2, interact with His<sub>6</sub>-CaM in a Ca<sup>2+</sup>-dependent manner (Ca<sup>2+</sup>: 500 &#956;M), as binding is abolished in the presence of the Ca<sup>2+</sup>-chelator, EGTA (10 mM). A negative control pseudokinase, MLKL, did not detectably bind CaM. CaM interaction was detected using an anti-His<sub>6</sub> HRP antibody. data are representative of two independent replicates. (<bold>C</bold>) CHK2 is inhibited by Ca<sup>2+</sup>-CaM. Full-length wildtype and K249A kinase-dead CHK2 were immunoprecipitated and activity was measured by radiometric assay containing 200 &#8201;&#956;M CHKtide, 200 &#8201;&#956;M [<sup>32</sup>P]-&#947;-ATP and in the presence (red) or absence (white) of 200 &#8201;&#956;M CaCl<sub>2</sub>, 1 &#8201;mM CaM for 10 &#8201;min. Two-way ANOVA; ****<italic toggle="yes">P</italic>&lt;0.0001; n.s = non-significant. (<bold>D</bold>) Double referenced SPR sensorgrams for immobilised full-length CHK2 binding to analyte, Ca<sup>2+</sup>-CaM. Shown is a representative sensorgram that is colour-coded based on CaM concentration. (<bold>E</bold>) Steady state analysis for the SPR experiment shown in (<bold>D</bold>), along with the dissociation constant. (<bold>F</bold>) Titration of CaM (range 0, 0.5, 1, 2, 5, 10, 20, 50, 100, 200 &#956;M) using immunoprecipitated full-length CHK2 (~10 ng) in the presence of 1 &#8201;mM CaCl<sub>2</sub> by radiometric assay. The half-maximal inhibitory concentration (IC<sub>50</sub>) for CaM is 8.1 &#956;M. Data represent mean &#177; SD; <italic toggle="yes">n</italic> = 3. (<bold>G</bold>) Plot of highest and lowest CHK2 kinase activity from CaM titration the presence of 1 &#8201;mM CaCl<sub>2</sub>. Individual data points are shown as circles with accompanying mean &#177; SD; <italic toggle="yes">n</italic> = 3. Statistical analysis was performed by unpaired t-test; ****<italic toggle="yes">P</italic>&lt;0.0001. (<bold>H</bold>) Titration of CaCl<sub>2</sub> (range 0, 1, 2, 5, 10, 20, 50, 100, 200, 500, 1000 &#956;M) using immunoprecipitated full-length CHK2 (~10 ng) in the presence of 200 &#956;M CaM by radiometric assay. the IC<sub>50</sub> of CHK2 and CaM by Ca<sup>2+</sup> is 30.7 &#956;M. Data represent mean &#177; SD; <italic toggle="yes">n</italic> = 3. (<bold>I</bold>) Plot of highest and lowest CHK2 kinase activity from CaCl<sub>2</sub> titration in the presence of 200 &#956;M CaM. individual data points are shown as circles with accompanying mean &#177; SD; <italic toggle="yes">n</italic> = 3. Statistical analysis was performed by unpaired t-test; ***<italic toggle="yes">P</italic>&lt;0.001. (<bold>J</bold>) Schematic of the amino acid residues of recombinant full-length CHK2 and CaM (red) chemically cross-linked by DMTMM (&#8216;zero-length&#8217;) and (<bold>K</bold>) photoactivatable cross-linker, NHS-Diazarine (SDA; 3.9 &#197; spacer), following mass-spectrometry analysis. Cross-links (grey) are only observed within the CHK2 kinase domain (blue) for both chemical cross-linkers. (<bold>L</bold>) Six lysine residues in CHK2, identified by DMTMM chemical cross-linking are mapped to the domain architecture of CHK2. (<bold>M</bold>) Radiometric assay of immunoprecipitated CHK2 wildtype and select cross-linked lysine mutants in the presence (red) or absence (white) of 200 &#8201;&#956;M CaCl<sub>2</sub>, 1 &#8201;mM CaM for 10 &#8201;min. Note: wildtype and K249A kinase-dead data are reproduced from (<bold>C</bold>). Data represent mean &#8201;&#177;&#8201; SD; <italic toggle="yes">n</italic> = 3. Statistical analysis was performed by two-way ANOVA; * and ****<italic toggle="yes">P</italic>&lt;0.1 and <italic toggle="yes">P</italic>&lt;0.0001, respectively; n.s = non-significant. Assay data using recombinant CHK2 kinase domain with each cross-linked lysine mutant are shown in <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 4B</xref>.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bcj-482-23-BCJ20253431-g001.jpg"/></fig><p>We next tested the impact on CHK2 catalytic activity by performing radiometric kinase assays on immunoprecipitates of full-length CHK2 from HEK293T cells. Surprisingly, these assays revealed that CHK2 activity was attenuated ~10 fold by CaM (<xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1C</xref>). We confirmed this activity was attributable to CHK2 and not a contaminating kinase, as the K249A kinase-dead mutant, in which the ATP-positioning &#946;3 lysine of the VAIK motif was substituted to Ala, was incapable of measurable phosphotransfer (<xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1C</xref>). Comparable results were obtained using an orthogonal fluorometric assay, providing further support for CaM interacting with CHK2 and inhibiting its catalytic activity (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 1A</xref>). To investigate whether phosphorylation of CHK2 played a role in the allosteric inhibition by Ca<sup>2+</sup>-CaM, immunoprecipitates of CHK2 were treated with &#955; phosphatase prior to radiometric assay and validated as dephosphorylated by PhosTag gel analysis (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 1B</xref>). Basal kinase activity and inhibition by Ca<sup>2+</sup>-CaM was comparable with or without &#955; phosphatase treatment (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 1C</xref>), indicating that Ca<sup>2+</sup>-CaM interaction and inhibition of CHK2 activity are independent of CHK2 phosphorylation status.</p><p>We next asked whether CHK2 and CaM directly interact using surface plasmon resonance (SPR). We immobilised full-length recombinant CHK2 to the sensor surface via a C-terminally fused, biotinylated AviTag and examined binding to the analyte, Ca<sup>2+</sup>-CaM. These experiments supported a direct interaction between Ca<sup>2+</sup>-CaM and CHK2, with a low micromolar affinity (<italic toggle="yes">K<sub>d</sub>
</italic> = 21.6 &#177; 4.7 &#956;M) (<xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1D&#8211;E</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 2</xref>). To further validate this complex interaction, we titrated CaM (0, 0.5, 1, 2, 5, 10, 20, 50, 100, 200 &#956;M) in our radiometric assay. Concordantly, these titrations yielded half-maximal inhibition (IC<sub>50</sub>) values for CHK2 by Calmodulin of 8.09 &#956;M (<xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1F&#8211;G</xref>), consistent with direct interaction of Ca<sup>2+</sup>-CaM with CHK2 to inhibit catalytic activity. Additionally, we sought to determine the Ca<sup>2+</sup> dependence of CaM with CHK2 by titrating Ca<sup>2+</sup> up to 1 mM in our radiometric assay. These titrations yielded an IC<sub>50</sub> of CHK2 by CaM at 30.7 &#956;M Ca <sup>2+</sup> (<xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1H&#8211;I</xref>), which are values typical for CaM [<xref rid="BCJ-2025-3431C1" ref-type="bibr">1</xref>]. Notably, Ca<sup>2+</sup> or CaM alone did not affect CHK2 activity, thereby asserting the importance of Ca<sup>2+</sup> for promoting a conformation of CaM competent for CHK2 recognition and inhibition.</p><p>Having established a direct inhibitory interaction between Ca<sup>2+</sup>-CaM and CHK2, we mapped the site of interaction using cross-linking mass spectrometry with the zero-length cross-linker, DMTMM (<xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1J</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 3A</xref>) and the photoactivatable cross-linker, SDA (<xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1K</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 3B</xref>). Using either cross-linker, interactions with CaM were confined to the CHK2 kinase domain, even though full length recombinant CHK2 was used in these studies. DMTMM cross-linking identified six lysines in CHK2 that were proximal to CaM in the complex (<xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1L</xref>). Cross-linking of each of the six CHK2 lysines to CaM suggests their proximity to CaM in the CHK2:CaM complex, but does not formally assert a role for each as a direct interactor. To determine whether any of the cross-linked CHK2 lysines were of functional importance to Ca<sup>2+</sup>-CaM binding, we prepared recombinant CHK2 kinase domain (amino acids 210&#8211;531) containing individual Lys to Ala substitutions to examine their susceptibility to Ca<sup>2+</sup>-CaM inhibition (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 4A</xref>). One substitution, K249A, mutated the canonical ATP-binding lysine of the VAIK motif, which eliminated its catalytic activity, as expected. K245A CHK2 retained sensitivity to Ca<sup>2+</sup>-CaM inhibition, whereas K255A, K373A and K465A CHK2 exhibited diminished sensitivity to Ca<sup>2+</sup>-CaM inhibition. Importantly, the introduction of the K255A and K373A CHK2 mutations did not compromise basal catalytic activity, while the K465A mutation caused a modest attenuation likely to be confined to an effect of the mutation on the core kinase domain, as this effect was not evident in full-length CHK2. K437A CHK2 was poorly expressed as a core kinase domain construct and exhibited a marked attenuation of basal catalytic activity and was therefore omitted from further analysis (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 4B</xref>). Retention of basal CHK2 catalytic activity, but loss of Ca<sup>2+</sup>-CaM modulation, supports roles for these residues in Ca<sup>2+</sup>-CaM engagement, rather than in CHK2 catalysis. To evaluate whether phosphorylation played a role in the allosteric inhibition by Ca<sup>2+</sup>-CaM, recombinant CHK2 kinase domain was treated with &#955; phosphatase prior to radiometric assay and validated as dephosphorylated by intact mass spectrometry (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 1D</xref>). Analogous to immunoprecipitates of full-length CHK2, the basal kinase activity and inhibition by Ca<sup>2+</sup>-CaM for the recombinant CHK2 kinase domain was comparable with or without &#955; phosphatase treatment (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 1E</xref>). To ensure these differences in Ca<sup>2+</sup>-CaM sensitivity were not attributable to compromised protein folding, we evaluated each variant&#8217;s thermal stability by differential scanning fluorimetry. All mutant CHK2 (210-531) constructs, except K465A CHK2, exhibited melting temperatures (<italic toggle="yes">T</italic>
<sub>m</sub>) that were comparable with wildtype (ranging from 39 to 44&#176;C; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 4C</xref>), demonstrating that these constructs were correctly folded. Notably, K249R CHK2 was previously successfully crystallised [<xref rid="BCJ-2025-3431C19" ref-type="bibr">19</xref>], suggesting this mutation is likely to exhibit greater stability than the Ala substitution used herein. K465A displayed a lower <italic toggle="yes">T</italic>
<sub>m</sub> (28&#176;C) suggesting partial destabilisation or increased flexibility of this mutant, which would explain the lower basal catalytic activity (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure 4B</xref>). An apparent <italic toggle="yes">T</italic>
<sub>m</sub> could not be obtained for K249A CHK2 due to high background fluorescence. Reduced thermal stability for K249A CHK2 is not surprising, because this mutation would disrupt interaction of the ATP-binding Lys with the &#945;C-helix Glu (E274), an interaction typical of a canonical kinase active state.</p><p>We next prepared full-length CHK2 by immunoprecipitating wildtype and mutant variants exogenously expressed in HEK293T cells to validate our observations made using purified recombinant kinase domains. Consistent with our findings with recombinant CHK2 kinase domains, immunoprecipitated full-length K245A CHK2 was basally active but inhibited ~10 fold by Ca<sup>2+</sup>-CaM, whereas K373A CHK2 retained basal activity but was not susceptible to Ca&#178;<sup>+</sup>-CaM inhibition, further supporting the role of K373 in Ca&#178;<sup>+</sup>-CaM engagement (<xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1M</xref>).</p></sec><sec id="s2-2"><title>CaM wraps around the CHK2 kinase domain to inhibit activity</title><p>We next detailed the interaction of the CHK2 kinase domain with Ca<sup>2+</sup>-CaM using biophysical methods. Hydrogen-deuterium exchange mass spectrometry (HDX-MS) is a technique that measures the exchange rate of amide hydrogens, which acts as a readout of protein secondary structure dynamics [<xref rid="BCJ-2025-3431C23" ref-type="bibr">23</xref>]. HDX-MS can be employed to identify both direct and allosteric conformational changes accompanying ligand binding. HDX-MS has been used extensively to identify conformational changes accompanying protein kinase regulation, inhibition and activation [<xref rid="BCJ-2025-3431C24" ref-type="bibr">24&#160;26</xref>]. We used HDX-MS to map regions within full-length recombinant CHK2 with altered hydrogen-deuterium exchange in the presence of Ca<sup>2+</sup>-CaM, identifying regions centred on, and flanking, the active site cleft (<xref rid="BCJ-2025-3431F2" ref-type="fig">Figure&#160;2A&#8211;B</xref>). HDX-MS coverage spanned 78% of the primary sequence (<xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref>), with the full raw deuterium incorporation data for all generated peptides provided in the Extended Data.</p><fig position="float" id="BCJ-2025-3431F2" fig-type="figure" orientation="portrait"><label>Figure 2</label><caption><title>Mapping the Ca<sup>2+</sup>-CaM-binding surface of human CHK2.</title><p>
<bold>(A</bold>) Quantitative analysis of deuterium exchange differences of human CHK2 in the presence of Ca<sup>2+</sup>-CaM, following hydrogen-deuterium exchange mass spectrometry (HDX-MS). The graph shows the #D difference in deuterium incorporation for CHK2 over the entire time course. Each point represents an individual peptide, with those coloured in red showing a significant change (greater than 0.40 Da and 5% difference at any timepoint, with a two tailed <italic toggle="yes">t</italic>-test; <italic toggle="yes">P</italic>&lt;0.01, <italic toggle="yes">n</italic> = 3), with error bars showing standard deviation. CHK2 domain architecture is annotated above. (<bold>B</bold>) Significant differences in deuterium exchange are mapped onto an AlphaFold3 model of CHK2 and are colour-coded according to the legend. Zoomed view of the CHK2 active site cleft is shown on the right. Key catalytic residues and cross-linked lysine residues (from <xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1L</xref>) are annotated. (<bold>C</bold>) Cross-linking mass spectrometry data are mapped onto an AlphaFold model of CaM:CHK2. &#8216;Zero-length&#8217; DMTMM and SDA cross-links are shown in red and blue, respectively. Key catalytic residues of CHK2 are shown in yellow. (<bold>D</bold>) The electrostatic potential mapped onto the molecular surface of CHK2 reveals patches of positive charge that are proximal with residues in (<bold>C</bold>) and complement the negatively charged surface of CaM. (<bold>E</bold>) AlphaFold3 model of human CHK2 kinase domain (blue) in complex with CaM (red).</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bcj-482-23-BCJ20253431-g002.jpg"/></fig><p>Notably, owing to the solubilities of both CHK2 and CaM, these experiments were performed at sub-saturating concentrations of CaM. Nonetheless, these experiments successfully show decreased deuterium exchange in peptides encompassing residues 72&#8211;96, 97&#8211;106 and 123&#8211;130 in the FHA domain, in addition to peptides 203&#8211;218 and 205&#8211;220 at the junction with the kinase domain, and 353&#8211;363, 437&#8211;452 and 439&#8211;452 in the kinase domain, in the presence of Ca<sup>2+</sup>-CaM (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S5</xref>). These decreases in exchange are consistent with the cross-linking mass spectrometry data (<xref rid="BCJ-2025-3431F1" ref-type="fig">Figure&#160;1J and K</xref>; <xref rid="BCJ-2025-3431F2" ref-type="fig">Figure&#160;2C</xref>), where CaM wrapping around the CHK2 kinase domain would be expected to induce changes in hydrogen-deuterium exchange in the catalytic loop and flanking regions of the kinase domain. Accordingly, in the presence of Ca<sup>2+</sup>-CaM, reduced HDX was observed in peptides at the flexible FHA-kinase domain junction N-terminal to the kinase domain and at the neighbouring region in the FHA domain, and in the &#945;G and &#945;G&#8242; helices at the foot of the kinase domain C-lobe (<xref rid="BCJ-2025-3431F2" ref-type="fig">Figure&#160;2B&#8211;C</xref>). Mapping the electrostatic potential to the molecular surface of the CHK2 kinase domain reveals numerous patches of positive charge, which complement the highly negatively charged surface of CaM and are proximal to residues from our cross-linking experiments (<xref rid="BCJ-2025-3431F2" ref-type="fig">Figure&#160;2D</xref>). Our cross-linking mass spectrometry and HDX-MS data were further supported by an AlphaFold3 model of the CaM:CHK2 kinase domain complex, in which a bidentate interaction of CaM with the N- and C-lobes of CHK2, centred on the CHK2 catalytic loop, was observed (<xref rid="BCJ-2025-3431F2" ref-type="fig">Figure&#160;2E</xref>; Supplementary Figure S6). However, a more precise understanding of how CaM engages CHK2 awaits experimental structure determination.</p></sec><sec id="s2-3"><title>CHK2 K373A mutation diminishes cellular proliferation</title><p>We next sought to establish whether the key CaM-binding residues in CHK2 (K255, K373 and K465) identified by cross-linking mass spectrometry, and validated as important for Ca<sup>2+</sup>-CaM interaction biochemically, are crucial to CHK2&#8217;s cellular function. CHK2 is highly evolutionarily conserved, with orthologs known in animals and fungi (<xref rid="BCJ-2025-3431F3" ref-type="fig">Figure&#160;3A</xref>). Examination of orthologous sequences identified K373 of human CHK2 as almost universally conserved, with the only deviation being <italic toggle="yes">Trichoplax adhaerens</italic> where the Lys was conservatively substituted with Arg (<xref rid="BCJ-2025-3431F3" ref-type="fig">Figure&#160;3A</xref>). The extensive conservation of K373 suggested a conserved functional role, which warranted further investigation in a cellular context. By contrast, the other human CHK2 residues implicated in interaction with CaM, K255 and K465 (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S4B</xref>), are highly conserved as Lys or Arg in mammalian CHK2 orthologs, but are poorly conserved in other eukaryotes, and so less likely to serve an ancestral role in CaM recognition than K373. Accordingly, we focused our cellular examination of CaM regulation of CHK2 on the K373A mutant. Using CRISPR, we introduced an Ala substitution for K373 into the diploid, hTERT-immortalised, retinal pigment epithelial (RPE) cells [<xref rid="BCJ-2025-3431C27" ref-type="bibr">27</xref>] (<xref rid="BCJ-2025-3431F3" ref-type="fig">Figure&#160;3B</xref>; <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S7</xref>), which are routinely used to study the cell cycle [<xref rid="BCJ-2025-3431C28" ref-type="bibr">28</xref>]. Following CRISPR-knockin, analysis of cell proliferation using IncuCyte live cell imaging revealed that, while <italic toggle="yes">CHK2<sup>K373A</sup>
</italic> RPE cells grew, they exhibited muted proliferation compared with wildtype RPE cells (<xref rid="BCJ-2025-3431F3" ref-type="fig">Figure&#160;3C&#8211;D</xref>). These growth deficiencies for CHK2 were accentuated by exposure to the DNA damaging agent, Camptothecin (CPT), a topoisomerase I inhibitor [<xref rid="BCJ-2025-3431C29" ref-type="bibr">29</xref>] (<xref rid="BCJ-2025-3431F3" ref-type="fig">Figure&#160;3E</xref>). Cell proliferation of <italic toggle="yes">CHK2<sup>K373A</sup>
</italic> RPE cells was significantly reduced in the presence of 10 nM and 100 nM CPT compared with wildtype RPE cells (<xref rid="BCJ-2025-3431F3" ref-type="fig">Figure&#160;3F</xref>), as was evident in end-point micrographs (<xref rid="BCJ-2025-3431F3" ref-type="fig">Figure&#160;3G</xref>), despite comparable expression levels of wildtype and <italic toggle="yes">CHK2<sup>K373A</sup>
</italic> in these cells (<xref rid="BCJ-2025-3431F3" ref-type="fig">Figure&#160;3H</xref>). Importantly, activation loop phosphorylation on Thr383 is not compromised between wildtype and <italic toggle="yes">CHK2<sup>K373A</sup>
</italic> cells (<xref rid="BCJ-2025-3431F3" ref-type="fig">Figure&#160;3H</xref>), indicating that CRISPR-knock-in of the K373A mutation does not compromise CHK2 activation by autophosphorylation in cells.</p><fig position="float" id="BCJ-2025-3431F3" fig-type="figure" orientation="portrait"><label>Figure 3</label><caption><title>Mutation of evolutionarily conserved K373 of human CHK2 compromises cell proliferation.</title><p>
<bold>(A</bold>) Multiple sequence alignment of CHK2 orthologs, which highlights the conservation of CHK2 residues in animals and fungi (K255, K373 and K465; asterisk) implicated in interaction with Ca<sup>2+</sup>-CaM. Residues in the alignment are coloured according to the Clustal colouring scheme, which highlights chemical nature and patterns of conservation. (<bold>B</bold>) Chromatograms from Sanger sequencing confirm the successful integration of nucleotide changes for K373A in hTERT-immortalized RPE cells by CRISPR/Cas9. (<bold>C</bold>) Real-time proliferation analysis of wildtype and CRISPR-edited RPE cells using IncuCyte live-cell imaging, and (<bold>D</bold>) corresponding area under the curve. Data represent mean &#8201;&#177;&#8201; SD; <italic toggle="yes">n</italic> = 8. Statistical analysis was performed by paired <italic toggle="yes">t</italic>-test; ****<italic toggle="yes">P</italic>&lt;0.0001. (<bold>E</bold>) Real-time proliferation analysis of wildtype and CRISPR-edited RPE cells cultured in the presence of DNA damaging agent, camptothecin (CPT), at 10 nM and 100 nM, and (<bold>F</bold>) corresponding area under the curve. Data represent mean &#8201;&#177;&#8201; SD; <italic toggle="yes">n</italic> = 8. Statistical analysis was performed by two-way ANOVA; ****<italic toggle="yes">P</italic>&lt;0.0001. (<bold>G</bold>) Raw micrographs of cell confluence exported from the IncuCyte SX3 system after 72 h incubation; the scale bars (black) represent 100 &#181;m. (<bold>H</bold>) Whole cell-lysates of hTERT-immortalised RPE cells (wildtype and <italic toggle="yes">CHK2<sup>K373A</sup>
</italic>) were resolved by SDS-PAGE and probed by immunoblot for phospho-CHK2 (Thr383) and total CHK2 with anti-actin as a loading control. Immunoblots are representative of <italic toggle="yes">n</italic> &#8201;&#8201;=&#8201; 2 independent experiments.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bcj-482-23-BCJ20253431-g003.jpg"/></fig><p>By extension from our findings with recombinant K373A CHK2, which lost sensitivity to CaM inhibition in <italic toggle="yes">in vitro</italic> kinase assays, our cellular data support a role for the CHK2 activation loop &#8211; centred on K373 &#8211; in CaM engagement. We note, however, that lysine residues, such as K373, may be subject to post-translational modification in cellular environments, which complicates interpretation of cellular proliferation data. While further cellular studies are required for complete validation, our data are consistent with the loss of CaM interaction compromising cell cycle progression in response to Ca<sup>2+</sup> flux following the DNA damage response (<xref rid="BCJ-2025-3431F4" ref-type="fig">Figure&#160;4</xref>).</p><fig position="float" id="BCJ-2025-3431F4" fig-type="figure" orientation="portrait"><label>Figure 4</label><caption><title>
<bold>Schematic model of CHK2 activation and CaM-mediated regulation of cell cycle progression</bold>.</title><p>Following DNA damage, the upstream kinase, ATM (green), phosphorylates Thr68 within the CHK2 SCD, which leads to the formation of a transient homodimer, mediated by the CHK2 FHA domains binding to pThr68. This dimerization results in CHK2 activation loop phosphorylation on T383 <italic toggle="yes">in trans</italic> and increased catalytic activity. Following activation, CHK2 phosphorylates multiple substrates, including CDC25C, BRCA1, HDMX, PLK1 and TP53, to promote cell cycle arrest and impede DNA repair. Upon sensing increased Ca<sup>2+</sup> levels, CaM can directly interact with the CHK2 kinase domain to inhibit catalytic activity and enable cell cycle progression and DNA repair.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bcj-482-23-BCJ20253431-g004.jpg"/></fig></sec></sec><sec sec-type="discussion" id="s3"><title>Discussion</title><p>Kinases of the CAMK1 and CAMK2 families are known to be activated by Ca<sup>2+</sup>-CaM sequestering an autoinhibitory sequence C-terminal to the kinase domain, to relieve autoinhibition of the kinase domain (<xref rid="BCJ-2025-3431F5" ref-type="fig">Figure&#160;5</xref>). Elsewhere among the CAMK family, few members are predicted to harbour CaM-binding sequences and, rather than association with Ca<sup>2+</sup>-CaM regulation, have been classified in the CAMK family owing to their sequence homology. Accordingly, in the absence of CaM-binding sequences, whether they are CaM regulated has not been established and, if they are, the underlying mechanism remains undetailed.</p><fig position="float" id="BCJ-2025-3431F5" fig-type="figure" orientation="portrait"><label>Figure 5</label><caption><title>Comparison of known modes of Ca<sup>2+</sup>-CaM regulation of protein kinases.</title><p>
<bold>(A</bold>) Ca<sup>2+</sup>-CaM-dependent protein kinase II (PDB 2WEL) [<xref rid="BCJ-2025-3431C10" ref-type="bibr">10</xref>]; (<bold>B</bold>) Death-associated protein kinases (DAPK)-1 (PDB 2X0G) [<xref rid="BCJ-2025-3431C11" ref-type="bibr">11</xref>]; and (<bold>C</bold>) DAPK2 (PDB 6PAW) [<xref rid="BCJ-2025-3431C12" ref-type="bibr">12</xref>] harbor a conventional CaM-binding sequence C-terminal to the protein kinase domain. (<bold>D</bold>) GPCR kinase 5 (GRK5; PDB 6PJX) [<xref rid="BCJ-2025-3431C13" ref-type="bibr">13</xref>] interacts with Ca<sup>2+</sup>-CaM via two helical regions N- and C-terminal to the protein kinase domain. (<bold>E</bold>) Ca<sup>2+</sup>-CaM directly interacts with the protein kinase domain of CHK2 (AlphaFold model; from this study). Each mode of Ca<sup>2+</sup>-CaM regulation is illustrated in a Richardson (ribbons) diagram (top panel) and schematic representation (lower panel). The protein kinase domain is coloured blue, while other domains are grey. CaM and CaM-binding sequences (CaMBS) are coloured red and orange, respectively. Ca<sup>2+</sup> ions are coloured yellow.</p></caption><graphic xmlns:xlink="http://www.w3.org/1999/xlink" position="float" orientation="portrait" xlink:href="bcj-482-23-BCJ20253431-g005.jpg"/></fig><p>Here, we identify binding of Ca<sup>2+</sup>-CaM to the kinase domain of CHK2 (<xref rid="BCJ-2025-3431F5" ref-type="fig">Figure&#160;5</xref>), which, unlike typical Ca<sup>2+</sup>-CaM activation of CAMK family kinases [<xref rid="BCJ-2025-3431C2" ref-type="bibr">2</xref>,<xref rid="BCJ-2025-3431C14" ref-type="bibr">14</xref>], inhibits CHK2 activity. There are precedents for direct engagement of Ca<sup>2+</sup>-CaM with the kinase domain or sites N-terminal to the kinase domain from the world of plant kinases, which promote catalytic activity, although it is important to note that these attributions are based primarily on Ca<sup>2+</sup>-CaM binding to synthetic peptides rather than native kinase domains [<xref rid="BCJ-2025-3431C30" ref-type="bibr">30&#160;32</xref>]. Here, we identified the catalytic loop and flanking regions in the N- and C-lobes of the CHK2 kinase domain as the site of CaM binding. K373 in the activation loop of the CHK2 kinase domain, which is almost absolutely conserved throughout evolution, was essential for cell cycle progression following DNA damage. CHK2 is known to phosphorylate CDC25C, BRCA1, HDMX, PLK1 and TP53 [<xref rid="BCJ-2025-3431C33" ref-type="bibr">33&#160;36</xref>], which antagonises their promotion of cell cycle arrest and DNA repair. Accordingly, Ca<sup>2+</sup> flux following DNA damage repair will enable CaM-mediated blockade of CHK2-mediated effector phosphorylation, which will in turn relieve their inhibition and enable cell cycle progression (<xref rid="BCJ-2025-3431F4" ref-type="fig">Figure&#160;4</xref>). Importantly, our binding experiments identified a <italic toggle="yes">K<sub>d</sub>
</italic> ~20 &#956;M for interaction of Ca<sup>2+</sup>-CaM to CHK2. Such an affinity would allow lability, such as during flux in Ca<sup>2+</sup> levels within the nucleus that would modulate CaM conformation towards the CHK2-binding-competent form, as well as ensure inhibitory CaM binding only upon high local concentrations in the nucleus. The best characterised mode of attenuation of the activities of CHK2 and other CAMK kinases is phosphatase-mediated dephosphorylation to disarm their kinase activity or transactivation [<xref rid="BCJ-2025-3431C37" ref-type="bibr">37</xref>,<xref rid="BCJ-2025-3431C38" ref-type="bibr">38</xref>]. Here, we add direct binding to the kinase domain as another mechanism by which Ca<sup>2+</sup>-CaM can negate CHK2 activity and block phosphorylation of downstream substrates to enable cell cycle progression and DNA repair.</p><p>Broadly, our findings expand knowledge on the mechanisms by which Ca<sup>2+</sup>-CaM can regulate kinase activity. Typically, Ca<sup>2+</sup>-laden CaM wraps around helical peptide sequences with hydrophobic residues in the target sequence inserting into an anchor pocket in addition to one or more regularly spaced hydrophobic pockets in CaM [<xref rid="BCJ-2025-3431C5" ref-type="bibr">5</xref>]. The helix connecting the two EF-hand domains of CaM allows for some flexibility in binding mode, such that the spacing of hydrophobic residues in the target sequence can vary by one or more helical turns, and dictate whether Ca<sup>2+</sup>-CaM binds in a compact or elongated form. Structural knowledge of these binding modes has enabled prediction of sequences that conform to typical CaM-binding sequences. However, the concept of Ca<sup>2+</sup>-CaM binding three-dimensional surfaces, rather than helical motifs, has only recently emerged. Cross-linking mass spectrometry and enzymatic studies previously recently identified direct binding of Ca<sup>2+</sup>-CaM to the PSKH1 kinase domain in promoting catalytic activity [<xref rid="BCJ-2025-3431C15" ref-type="bibr">15</xref>]. In contrast, binding of another Ca<sup>2+</sup> sensor, Reticulocalbin-3, to PSKH1&#8217;s kinase domain suppressed catalytic activity [<xref rid="BCJ-2025-3431C15" ref-type="bibr">15</xref>], indicating that the mode of interaction with the kinase domain, rather than the interaction itself, is crucial to tuning kinase catalytic activity. Additionally, the lability of CaM binding to kinase targets is likely to be of functional importance. PSKH1 bound CaM with an EC<sub>50</sub> of 59 nM, with high Ca<sup>2+</sup> concentrations licensing Reticulocalbin-3 to compete with CaM for PSKH1 binding to suppress catalytic activity, providing an off switch [<xref rid="BCJ-2025-3431C15" ref-type="bibr">15</xref>].</p><p>As in the case with CaM promotion of PSKH1 activation, precise knowledge of the allosteric mechanism underlying CaM inhibition reported herein, and mapping of the CaM:CHK2 interface, awaits a high resolution structure. Nevertheless, our data suggest Ca<sup>2+</sup>-CaM would inhibit CHK2 activity by occluding the substrate-binding site because Ca<sup>2+</sup>-CaM binding is centred on the CHK2 catalytic loop. A high-resolution structure will likely be important to defining whether Ca<sup>2+</sup>-CaM imposes more severe structural perturbations, such as by freezing CHK2 in an inactive conformation or disrupting the regulatory &#8216;R&#8217;-spine of hydrophobic interactions required for an active conformation [<xref rid="BCJ-2025-3431C39" ref-type="bibr">39</xref>]. Regardless, our data support the idea that Ca<sup>2+</sup>-CaM binding to CHK2 acts downstream of CHK2&#8217;s activation through homodimerisation rather than acting on homodimers themselves. CHK2 dimerisation mediated by the N-terminal FHA domain binding <italic toggle="yes">in trans</italic> is reported to be a key step in activation; however, Ca<sup>2+</sup>-CaM inhibited CHK2 independently of phosphorylation status. Thus, our data indicate the Ca<sup>2+</sup>-CaM acts on monomeric CHK2 to block its activity towards substrates.</p><p>Our findings highlight an underappreciated role for Ca<sup>2+</sup>-CaM as an inhibitor of protein kinase activity, which complements its well-established role as an activator of CAMK kinase activities via sequestration of autoinhibitory sequences. Additionally, it remains of interest to understand whether kinases, like CHK2 and PSKH1 in the CAMK family and beyond, which lack a predicted CaM-binding sequences, can be regulated by Ca<sup>2+</sup>-CaM binding through non-canonical binding modes, such as the mode we describe here: direct kinase domain binding. Whether these additional modes of kinase regulation by Ca<sup>2+</sup>-CaM serve ancestral functions remains of outstanding interest for future studies. Our findings underscore the structural and functional plasticity of Ca<sup>2+</sup>-CaM as a regulator of enzymatic activities and suggest that the diversity of Ca<sup>2+</sup>-CaM&#8217;s allosteric activities may be greater than currently documented.</p></sec><sec sec-type="materials|methods" id="s4"><title>Materials and methods</title><sec id="s4-1"><title>Reagents and antibodies</title><p>Primary antibodies used in this study for immunoblotting were: rabbit anti-His<sub>6</sub>-HRP-conjugated (Abcam; clone ab1187: 1:5000); rat anti-FLAG (WEHI clone 9H1; produced in-house; 1:1000); rabbit anti-phospho-Thr383 CHK2 (ThermoFisher; catalog PA5-104714; 1:1000); mouse anti-CHK2 (Cell Signaling Technology; clone 1C12; 1:1000); mouse anti-actin, (Sigma-Aldrich, A-1978; 1:1000). Secondary antibodies used in this study were: horseradish peroxidase (HRP)-conjugated goat anti-rat IgG (Southern Biotech 3010&#8211;05), HRP-conjugated goat anti-mouse IgG (Southern Biotech 1010&#8211;05) and HRP-conjugated goat anti-rabbit IgG (Southern Biotech 4010&#8211;05). All secondary antibodies were used at a dilution of 1:10,000. Blots were visualised using Immobilon Forte Western HRP substrate (Millipore).</p></sec><sec id="s4-2"><title>Expression constructs</title><p>The gene coding for full-length human CHK2 (Uniprot <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="O96017">O96017</ext-link>) was synthesised by Gene Universal (Delaware, U.S.A.) and sub-cloned into the mammalian expression vector, pcDNA3.1(-), using the restriction sites XhoI and HindIII with an N-terminal FLAG tag. Individual Ala substitutions were also synthesised (Gene Universal) and subcloned into pcDNA3.1(-) as XhoI-HindIII fragments with an N-terminal FLAG tag. Full-length CHK2 and the CHK2 kinase domain (residues 210
&#8211;
531)
were subcloned into the bacterial expression vector, pGEX-2-TEV [<xref rid="BCJ-2025-3431C40" ref-type="bibr">40</xref>], as an in-frame fusion with a TEV protease-cleavable N-terminal GST tag using ligation-independent cloning. For SPR studies, full-length CHK2 was subcloned into the insect expression vector, pFastBac GST, as an in-frame fusion with a TEV protease-cleavable N-terminal GST tag and C-terminal AviTag using ligation-independent cloning. The gene coding for full-length CaM (Uniprot <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="P0DP29">P0DP29</ext-link>) was synthesised by IDT (Iowa, U.S.A.) as a gBlock and subcloned into the bacterial expression vector, pPROEX Htb (Life Technologies), as an in-frame fusion with a TEV protease-cleavable N-terminal hexahistidine tag. Oligonucleotide sequences are presented in <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S1</xref>. Insert sequences were verified by Sanger sequencing (AGRF, VIC, Australia).</p></sec><sec id="s4-3"><title>Transient expression and immunoprecipitation</title><p>Full-length CHK2 (wildtype) was expressed in HEK293T cells grown in DMEM media (ThermoFisher Scientific), supplemented with 8% (v/v) Fetal Calf Serum (FCS; Sigma) at 37&#176;C with 10% CO<sub>2</sub>. The cells were transfected at 60% confluency using FuGene HD (Promega) with 2 &#181;g of pcDNA3.1(-) plasmid containing C-terminal FLAG-tagged human CHK2. After 48 h, transfected cells were harvested by rinsing with ice-cold PBS, followed by rapid lysis <italic toggle="yes">in situ</italic> using lysis buffer (50 &#8201;mM Tris-HCl pH 7.4, 1% (v/v) Triton X-100, 1 &#8201;mM PMSF, 1 &#8201;mM EDTA, 150 &#8201;mM NaCl, 2 &#8201;mM Sodium Vanadate, 10 &#8201;mM NaF) containing a Complete protease inhibitor tablet (Roche). Insoluble debris was removed by centrifugation and supernatants were mixed with 100 &#956;l of anti-FLAG M2 agarose (50% v/v; Millipore) pre-equilibrated in lysis buffer, followed by successive washes in lysis buffer containing 1 mM NaCl, and finally resuspended in 50 &#8201;mM HEPES, pH 7.4. For &#955; phosphatase treatments, the beads were incubated with recombinant &#955; phosphatase (produced in <italic toggle="yes">E. coli</italic> in-house) and 2 mM MnCl<sub>2</sub> for 1 h, before two washes in 50 &#8201;mM HEPES, pH 7.4. CHK2 was eluted off the beads by incubating overnight at 4&#176;C with 100 &#181;l of FLAG peptide (1 mg/ml) in 50 &#8201;mM HEPES, pH 7.4. Total protein content was quantified using the BCA Protein Assay (Thermo Fisher Scientific), according to manufacturer&#8217;s instructions.</p></sec><sec id="s4-4"><title>Recombinant expression and purification</title><p>Full-length CHK2 (residues 2&#8211;531), CHK2 kinase domain (residues 210&#8211;531) and CaM were primarily expressed in <italic toggle="yes">E. coli</italic> BL21-CodonPlus-RIL (Agilent) cells cultured in Super Broth supplemented with ampicillin (100 &#8201;&#181;g/ml) at 37&#176;C with shaking at 220 &#8201;rpm to an OD<sub>600</sub> of ~0.6&#8211;0.8. Protein expression was induced by the addition of isopropyl &#946;-D-1-thiogalactopyranoside (IPTG; 500 &#8201;&#181;M) and the temperature was lowered to 18&#176;C for incubation overnight.</p><p>CHK2 cell pellets were resuspended in GST buffer (20 &#8201;mM HEPES pH 7.5, 200 &#8201;mM NaCl, 10% v/v glycerol), supplemented with cOmplete Protease Inhibitor (Roche) and 0.5 &#8201;mM Bond-Breaker TCEP [tris-(2-carboxyethyl)phosphine] (ThermoFisher Scientific) and were lysed by sonication, before the lysate was clarified by centrifugation (40,000&#215;g, 45 &#8201;min, 4&#176;C). The proteins were maintained at 4&#176;C throughout purification. The clarified lysate was incubated with Glutathione Xpure Agarose resin (UBP-Bio) pre-equilibrated in GST buffer for &gt;1 &#8201;h on rollers at 4&#176;C, before the beads were pelleted at 500&#215;g and washed extensively with GST buffer. CHK2 was further purified by cleaving the GST tag (on resin) with recombinant His<sub>6</sub>-TEV protease overnight at 4&#176;C, followed by addition of Ni-NTA resin (cOmplete His-Tag; Roche) to eliminate TEV protease. For &#955; phosphatase treatments, GST-CHK2 loaded glutathione resin was incubated with recombinant &#955; phosphatase (produced in-house) and 2 mM MnCl<sub>2</sub> overnight at 4&#176;C (simultaneously with TEV). CaM cell pellets were resuspended in Ni-NTA buffer (20 &#8201;mM HEPES pH 7.5, 200 &#8201;mM NaCl, 10% v/v glycerol), supplemented with 10 &#8201;mM imidazole (pH 8.0), EDTA-free cOmplete Protease Inhibitor (Roche) and 0.5 &#8201;mM Bond-Breaker TCEP, and were lysed by sonication, before the lysate was clarified by centrifugation (40,000&#215;g, 45 &#8201;min, 4&#176;C). The clarified lysate was incubated with Ni-NTA resin (Roche) pre-equilibrated in Ni-NTA buffer with 5 &#8201;mM imidazole for &gt;1 &#8201;h on rollers at 4&#176;C, before the beads were pelleted at 500&#215;g and washed extensively with Ni-NTA buffer containing 35 &#8201;mM imidazole. The proteins were eluted in Ni-NTA buffer containing 250 &#8201;mM imidazole. The eluate was further purified by cleaving the His<sub>6</sub> tag using recombinant His<sub>6</sub>-TEV protease (for applications where the absence of His<sub>6</sub> tag was desirable), dialysis, Ni-NTA resin addition to eliminate uncleaved material and the TEV protease. Both cleaved samples were spin concentrated (10 or 30 &#8201;kDa MWCO; Millipore), before being loaded onto a HiLoad 16/160 Superdex 200 pg column (Cytiva) pre-equilibrated with SEC buffer (20 &#8201;mM HEPES pH 7.5, 200 &#8201;mM NaCl, 5% v/v glycerol). Purified fractions, as assessed following resolution by reducing StainFree SDS-PAGE gel electrophoresis (Bio-Rad), were pooled and spin concentrated to 5 &#8201;mg/ml (CHK2; 30 &#8201;kDa MWCO) or 50 &#8201;mg/ml (CaM; 10 &#8201;kDa MWCO) based on A<sub>280</sub> and extinction coefficient for each protein, aliquoted, and snap frozen in liquid N<sub>2</sub> for storage at &#8722;80&#176;C.</p><p>Full-length CHK2, harbouring a C-terminal AviTag for SPR studies, was expressed and purified from <italic toggle="yes">Sf</italic>21 insect cells, due to toxicity in <italic toggle="yes">E. coli</italic>, using established procedures [<xref rid="BCJ-2025-3431C41" ref-type="bibr">41</xref>,<xref rid="BCJ-2025-3431C42" ref-type="bibr">42</xref>]. Briefly, the bacmid was prepared in DH10MultiBac <italic toggle="yes">E. coli</italic> (ATG Biosynthetics) from a pFastBac GST vector encoding a TEV protease-cleavable GST fusion N-terminal to CHK2-AviTag. <italic toggle="yes">Sf</italic>21 insect cells (Merck) were cultured in Insect-XPRESS (Lonza) media. Each bacmid (1 &#956;g) was introduced into 0.9 &#8201;&#215;&#8201; 10<sup>6</sup>
<italic toggle="yes">Sf</italic>21 cells by Cellfectin II (Thermo Fisher Scientific) mediated transfection in six-well plates using the Bac-to-Bac protocol (Thermo Fisher Scientific). After four days of static incubation at 27&#176;C in a humidified incubator, the resulting P1 baculovirus was harvested and added to 50 &#8201;ml <italic toggle="yes">Sf</italic>21 cells at 0.5 &#8201;&#215;&#8201; 10<sup>6</sup> cells/ml density at 4% v/v, which were shaken at 27&#176;C, 130 &#8201;rpm. The cell density was monitored daily using a haemocytometer slide and maintained at 0.5&#8211;3.0 &#8201;&#215;&#8201; 10<sup>6</sup> cells/ml by diluting with fresh Insect-XPRESS media when necessary, until growth arrest (defined as a cell density less than the twice the cell count one day prior). Approximately 24 &#8201;h after growth arrest was recorded, the P2 baculovirus was harvested by collecting the supernatant after pelleting the cells at 500&#215;g for 5 &#8201;min. P2 baculovirus was added to 0.5&#8201;L <italic toggle="yes">Sf</italic>21 cells cultured at 1&#8211;1.5 &#8201;&#215;&#8201; 10<sup>6</sup> cells/ml in 2.8&#8201;L Fernbach flasks at 0.2% v/v, and cultured at 27&#176;C, 90 &#8201;rpm, until 24 &#8201;h post growth arrest. Cells were harvested at 500&#215;g and pellets snap frozen in liquid N<sub>2</sub> and either thawed immediately for lysis or stored at &#8722;80&#176;C. <italic toggle="yes">Sf</italic>21 cell pellets were lysed and purified by following an analogous protocol to GST-tagged CHK2 expressed in <italic toggle="yes">E. coli</italic>. Full-length human MLKL for the Far-Western Overlay Assay was expressed and purified from <italic toggle="yes">Sf</italic>21 insect cells as an N-terminal GST fusion, and purified analogously to CHK2 above, as previously [<xref rid="BCJ-2025-3431C41" ref-type="bibr">41</xref>,<xref rid="BCJ-2025-3431C42" ref-type="bibr">42</xref>].</p></sec><sec id="s4-5"><title>Far-Western overlay assay</title><p>Full-length recombinant proteins were spotted onto nitrocellulose membrane (2 &#181;l; ~2 &#181;g), blocked with 5% w/v skim milk powder in TBST, and probed overnight with recombinant His<sub>6</sub>-tagged CaM (1 mg/ml; produced in-house; 1:1000 dilution) and 200 &#956;M CaCl<sub>2</sub>. Control experiments, in the presence of 10 mM EGTA, to chelate Ca<sup>2+</sup> ions, were performed analogously. After incubation, membranes were rinsed 3 &#215; 5 min with TBST. CaM was detected using rabbit anti-His<sub>6</sub>-HRP-conjugated antibody (Abcam ab1187; 1:5000 dilution). Far-Western signals were visualised by chemiluminescence with Immobilon Forte Western HRP substrate (Millipore) using a ChemiDoc Imaging System (Bio-Rad).</p></sec><sec id="s4-6"><title>CHK2 kinase assays</title><p>CHK2 activity was determined by measuring the transfer of radiolabelled phosphate from [&#947;-<sup>32</sup>P]-ATP to a synthetic peptide substrate (CHKtide; KKKVSRSGLYRSPSMPENLNRPR), synthesised from GenScript (New Jersey, USA). Briefly, purified recombinant CHK2 (CHK2<sup>210-531</sup>; 10 ng) or immunoprecipitated full-length CHK2 (~10 ng; estimated from BCA assay quantitation) were incubated in assay buffer (50 mM HEPES, pH 7.4, 1 mM DTT) containing 200 &#956;M CHKtide, 1 mM CaCl<sub>2</sub>, 200 &#956;M recombinant CaM (produced in-house; expressed and purified from <italic toggle="yes">E. coli</italic>), 200 &#956;M [<sup>32</sup>P]-&#947;-ATP (Perkin Elmer, MA, USA), 5 mM MgCl<sub>2</sub> (Sigma) in a standard 30 &#956;l assay for 10 min at 30&#176;C. Reactions were terminated by spotting 15 &#956;l onto phosphocellulose paper (SVI-P; St Vincent&#8217;s Institute, Melbourne) and washing extensively in 1% phosphoric acid (Sigma). Radioactivity was quantified by liquid scintillation counting. CHK2 activity was also measured using an ADP-Glo kinase assay kit (Promega), following standard procedures. Briefly, a 10 &#956;l kinase reaction was assembled, containing 50 ng purified recombinant CHK2<sup>210-531</sup> or immunoprecipitated full-length CHK2, 200 &#956;M CHKtide, 1 mM CaCl<sub>2</sub>, 200 &#956;M recombinant CaM (produced in-house), and 200 &#956;M ATP in kinase buffer (50 mM HEPES pH 7.5, 20 mM MgCl<sub>2</sub>, 2 mM MnCl<sub>2</sub>, 1 mM TCEP). Each reaction was performed at 30&#176;C for 30 min and terminated by the addition of the ADP-Glo reagent. Following a 40 min incubation with the ADP-Glo reagent, the Kinase Detection reagent was added and luminescence was detected with a microplate reader (CLARIOstar, BMG LabTech) after 30 min.</p></sec><sec id="s4-7"><title>Intact mass spectrometry</title><p>Recombinant CHK2 proteins (1 mg/ml) were resolved by reverse-phase chromatography on a 25 cm ProSwift RP-4H monolith column (Thermo Scientific) using a micro-flow HPLC (Ultimate 3000). The HPLC was coupled to a Maxis II Q-TOF mass spectrometer (Bruker) equipped with an ESI source. Proteins were loaded directly onto the column for online buffer exchange at a constant flow rate of 50 &#181;l/min with buffer A (99.9% Milli-Q water, 0.1% FA) using a valve to direct flow to waste. After 10 min, the valve was switched to direct flow to the mass spectrometer, and proteins were eluted with a 10 min linear gradient from 2 to 90% buffer B (99.9% ACN, 0.1% FA). The Maxis II Q-TOF was operated in full MS mode using Compass Hystar 5.1. Mass spec settings were as follows: Mass Range 100 to 3000 m/z, Capillary Voltage 4500V, Dry Gas 4 l/min, Dry Temp 200&#176;C. Data were analysed with DataAnalysis version 5.2 (Bruker), and proteins were deconvoluted using the maximum entropy method.</p></sec><sec id="s4-8"><title>Phos-Tag gel preparation and analysis</title><p>A 5.5% acrylamide gel was prepared following the instructions of the Phos-Tag reagent manufacturer, with final concentrations of 375 mM Tris-HCl pH 8.8, 5.5% Acrylamide/Bis-acrylamide 29:1, 0.1% SDS, 50 &#181;M Phos-Tag AAL (FUJIFILM Wako Chemicals) and 100 &#181;M MnCl<sub>2</sub>, with 25 &#181;l 10% ammonium persulfate and 5 &#181;l TEMED, in the resolving gel, and final concentrations of 125 mM Tris-HCl pH 6.8, 5.5% acrylamide/bis-acrylamide 29:1, 0.1% SDS, with 25 &#181;l 10% ammonium persulfate and 5 &#181;l TEMED, in the stacking gel. Protein ladder was supplemented with 5 mM MnCl<sub>2</sub> to quench residual EDTA. Phos-Tag gels were run for ~150 min at 180 V until the Bromophenol Blue dye front ran to the foot of the gel. Proteins were then transferred to PVDF membrane, blocked with 5% w/v skim milk powder in TBST and then probed overnight with primary antibodies as per <italic toggle="yes">Reagents and antibodies</italic> above.</p></sec><sec id="s4-9"><title>Immunoblot</title><p>Samples were boiled at 100&#176;C for 5 &#8201;min in 1 &#8201;&#215;&#8201; SDS Laemmli lysis buffer (126 &#8201;mM Tris-HCl, pH 8, 20% v/v glycerol, 4% w/v SDS, 0.02% w/v Bromophenol Blue, 5% v/v 2-mercaptoethanol) and then resolved on a 4&#8211;15% Tris-Glycine (Bio-Rad) or Phos-Tag gel. Proteins were transferred to a PVDF membrane, blocked with 5% w/v skim milk powder in TBST and then probed overnight with primary antibodies (as per <italic toggle="yes">Reagents and antibodies</italic> above). The signals were visualised by enhanced chemiluminescence (Immobilon substrate; Millipore) on a ChemiDoc Touch Imaging System (Bio-Rad) following binding to an appropriate HRP-conjugated secondary antibody (as per <italic toggle="yes">Reagents and antibodies</italic> above).</p></sec><sec id="s4-10"><title>Site-specific biotinylation of CHK2-AviTag using recombinant BirA</title><p>Site-specific biotinylation of CHK2-AviTag (ASSSSSGLNDIFEAQKIEWHE) was carried out with His-Trx-BirA (produced in <italic toggle="yes">E. coli</italic> in-house), using established procedures [<xref rid="BCJ-2025-3431C43" ref-type="bibr">43</xref>]. Briefly, CHK2-AviTag was first dialysed into a low salt buffer consisting of 20 &#8201;mM HEPES pH 7.5, 200 &#8201;mM NaCl and 1 mM TCEP. CHK2 (100 &#181;M in 952 &#181;l of low salt buffer) was then mixed with magnesium chloride (5 &#181;l of 1M solution; Sigma), adenosine triphosphate (20 &#181;l of 100 mM solution; Sigma), His-Trx-BirA enzyme (20 &#181;l of 50 &#181;M solution) and D-Biotin (3 &#181;l of 50 mM solution in 100% DMSO; Sigma) and incubated for 1 h minimum at 30&#176;C in an incubator with gentle shaking (90 rpm). After &gt; 1 h, an additional equivalent of His-Trx-BirA and D-biotin were added and the reaction incubated for a further 1 h at 30&#176;C. Next, 100 &#181;l of a 50% slurry of Ni-NTA resin (Roche; pre-equilibrated into low salt buffer) was added to the reaction and incubated for 30 min at 4&#176;C to capture His-Trx-BirA. The resin was then pelleted at 500&#215;g and the supernatant spin concentrated (30 &#8201;kDa MWCO; Millipore), before being loaded onto a HiLoad 16/160 Superdex 200 pg column (Cytiva) pre-equilibrated with SEC buffer (20 &#8201;mM HEPES pH 7.5, 200 &#8201;mM NaCl, 5% v/v glycerol). The extent of biotinylation was evaluated by mixing with recombinant streptavidin before subjecting to reducing SDS-PAGE with StainFree imaging. With this assay, the gel shift indicated biotinylation was near stoichiometric. Biotinylated full-length CHK2 was concentrated to 2 &#8201;mg/ml, aliquoted and snap frozen in liquid N<sub>2</sub> for storage at &#8722;80&#176;C.</p></sec><sec id="s4-11"><title>Surface plasmon resonance</title><p>SPR was performed using a BIAcore 8K + instrument using a SA sensor chip (Cytiva) at 25&#176;C. Biotinylated full-length CHK2 (0.005 mg/ml) was immobilised in a buffer consisting of 20 &#8201;mM HEPES pH 7.5 and 200 &#8201;mM NaCl. Direct binding experiments were performed in running buffer (20 &#8201;mM HEPES pH 7.5, 200 &#8201;mM NaCl, 2 mM CaCl<sub>2</sub> and 0.005% Tween) with 240 sec injections and 200 sec dissociations at 25 &#181;l/min, using recombinant CaM (0&#8211;80 &#181;M; produced in-house) as the analyte. Flow cells were regenerated in 0.5 M NaCl with 30 sec injections at 30 &#181;l/min. Steady-state responses were determined in affinity evaluation mode using the BIAevaluation software and values plotted as a function of CaM concentration. All affinity measurements were performed in at least two independent experiments using independent protein preparations (Figure 1D&#8212;E; Supplementary Figure S2).</p></sec><sec id="s4-12"><title>Thermal shift assays</title><p>Thermal shift assays were performed as described previously [<xref rid="BCJ-2025-3431C44" ref-type="bibr">44</xref>] using a Corbett Real Time PCR machine with proteins diluted in 20 &#8201;mM HEPES, pH 7.5, 200 &#8201;mM NaCl to 10 &#8201;&#956;g in a total reaction volume of 25 &#8201;&#956;l. SYPRO Orange (Molecular Probes, CA) was used as a probe with fluorescence detected at 530 &#8201;nm. The melting temperature (<italic toggle="yes">T</italic>
<sub>m</sub>) corresponding to the midpoint for the protein unfolding transition was calculated by fitting the sigmoidal melt curve to the Boltzmann equation using GraphPad Prism. Two independent assays were performed for wildtype and mutant CHK2 constructs; averaged data are shown for each in <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S4C</xref>)</p></sec><sec id="s4-13"><title>Chemical cross-linking sample preparation</title><p>For DMTMM cross-linking, full-length recombinant CHK2 and CaM (1:5 molar ratio) were initially incubated on ice in 50 mM HEPES pH 7.5, 2 mM CaCl<sub>2</sub> for 30 min. The protein mixture (~3 &#956;g) was then incubated for 30 min at room temperature with a range of DMTMM concentrations (0, 5, 10, 20, 50 and 100 mM; Sigma, # 74104), which was prepared in 50 mM HEPES pH 7.5. Following incubation, each reaction was quenched with 100 mM Tris-HCl pH 7.5, mixed with reducing sample buffer, boiled at 100&#176;C for 5 min, then resolved by reducing SDS-PAGE gel electrophoresis (Bio-Rad). SDS-PAGE gels were stained using SimplyBlue SafeStain (ThermoFisher Scientific). For SDA cross-linking, recombinant full-length CHK2 and CaM (1:2 molar ratio) were initially incubated on ice in 50 mM HEPES pH 7.5, 2 mM CaCl<sub>2</sub> for 30 min. Protein (1.5 mg/ml) was then mixed with SDA (NHS-Diazirine; 1 mg/ml; Thermo Fisher, # 26167) and incubated in the dark for 30 min at room temperature to react the NHS-ester group. The diazirine group was then photo-activated using ultraviolet light irradiation (UVP CL-1000L UV cross-linker) at 365 nm. Samples were added to upturned lids excised from 1.5 ml microfuge tubes and placed on ice at a distance of 5 cm from the lamp and irradiated for 1 min. The reaction mixtures from the titration were combined and quenched with 100 mM Tris-HCl pH 7.5, mixed with reducing sample buffer, boiled at 100&#176;C for 5 min, then resolved by reducing SDS-PAGE gel electrophoresis (Bio-Rad). SDS-PAGE gels were stained using SimplyBlue SafeStain (ThermoFisher Scientific) (<xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S3</xref>) and cross-linked adducts excised for mass spectrometry analysis.</p></sec><sec id="s4-14"><title>Chemical cross-linking sample preparation for mass spectrometry-based proteomics</title><p>Protein gel bands were excised (based on their migration relative to the MW marker) and destained using 50% acetonitrile (ACN) for 30 min and 37&#176;C. The gel band was then dehydrated by adding 100% ACN and incubating at room temperature for 10 min, before aspirating the ACN and further drying the gel piece with the vacuum centrifuge (CentriVap, Labconco). Proteins were reduced by the addition of 1 mM dithiothreitol (DTT) in 50 mM ammonium bicarbonate for 30 min. Excess DTT was aspirated before the addition of 55 mM iodoacetamide to alkylate the sample for 60 min at room temperature. The gel slice was then washed with 50% acetonitrile twice and 100% ACN once before drying to completion in the vacuum centrifuge. Proteins were digested overnight with 500 ng trypsin in 50 mM ammonium bicarbonate at 37&#176;C and extracted the following day using 60% acetonitrile/0.1% formic acid. The collected peptides were lyophilised to dryness using a CentriVap (Labconco), before reconstituting in 10 &#181;l 0.1% formic acid/2% ACN ready for mass spectrometry analysis.</p></sec><sec id="s4-15"><title>Chemical cross-linking mass spectrometry analysis</title><p>Reconstituted peptides were analysed on Orbitrap Eclipse Tribrid mass spectrometer interfaced with Neo Vanquish liquid chromatography system. Samples were loaded onto a C18 fused silica column (inner diameter 75 &#181;m, OD 360 &#181;m &#215; 15 cm length, 1.6 &#181;m C18 beads) packed into an emitter tip (IonOpticks) using pressure-controlled loading with a maximum pressure of 1,500 bar using Easy nLC source and electro sprayed directly into the mass spectrometer.</p><p>We first employed a linear gradient of 3&#8211;30% of solvent-B at 400 nl/min flow rate (solvent-B: 99.9% (v/v) ACN) for 100 min, followed by a gradient of 30&#8211;40% solvent-B for 20 min and 35&#8211;99% solvent-B for 5 min. The column was then maintained at 99% B for 10 min before being washed with 3% solvent-B for another 10 min comprising a total of 145 min run with a 120 min gradient in a data-dependent (DDA) mode. MS1 spectra were acquired in the Orbitrap (<italic toggle="yes">R</italic> = 120 k; normalised AGC target = standard; MaxIT = Auto; RF Lens = 30%; scan range = 380&#8211;1400; profile data). Dynamic exclusion was employed for 30 s excluding all charge states for a given precursor. Data-dependent MS2 spectra were collected in the Orbitrap for precursors with charge states 3&#8211;8 (<italic toggle="yes">R</italic> = 50 k; HCD collision energy mode = assisted; normalised HCD collision energies = 25%, 30%; scan range mode = normal; normalised AGC target = 200%; MaxIT = 150 ms).</p></sec><sec id="s4-16"><title>Chemical cross-linking raw data processing and peptide identification</title><p>Raw data files were converted to MGF files using MS convert [<xref rid="BCJ-2025-3431C45" ref-type="bibr">45</xref>]. For DMTMM cross-linking analysis, peak files were searched using the MeroX software [<xref rid="BCJ-2025-3431C46" ref-type="bibr">46</xref>] (version 2.0.1.4) and a fasta file containing the full-length human CHK2 and CaM sequences. K to D or E residues were set as specificity sites for DMTMM cross-linking (-H<sub>2</sub>O). Trypsin was set as the enzyme allowing for three missed cleavages. Maximum peptide length was set to 40. Precursor precision was set at 10&#8201;ppm with fragment ion precision set at 20&#8201;ppm. For SDA cross-linking, MGF files were searched against a fasta file containing the CHK2 and CaM sequences using XiSearch software [<xref rid="BCJ-2025-3431C47" ref-type="bibr">47</xref>] (version 1.7.6.7) with the following settings: cross-linker = multiple, SDA and noncovalent; fixed modifications = carbamidomethylation (C); variable modifications = oxidation (M), SDA-loop (KSTY) DELTAMASS:82.04186484, SDA-hydro (KSTY) DELTAMASS:100.052430; MS1 tolerance = 6.0 ppm, MS2 tolerance = 20.0 ppm; losses = H<sub>2</sub>O,NH<sub>3</sub>, CH<sub>3</sub>SOH, CleavableCrossLinkerPeptide:MASS:82.04186484). FDR was performed with the in-built xiFDR set to 5%. Data were visualised using the XiView software [<xref rid="BCJ-2025-3431C48" ref-type="bibr">48</xref>]. Cross-linked peptide data are included in the Extended Data Excel file.</p></sec><sec id="s4-17"><title>Computational modelling of CHK2 and CaM</title><p>The sequence of full-length human CHK2 (Uniprot <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="O96017">O96017</ext-link>) and full-length human CaM (Uniprot <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" ext-link-type="pmc:entrez-protein" xlink:href="P0DP23">P0DP23</ext-link>) was used to generate a complex model using AlphaFold3 [<xref rid="BCJ-2025-3431C49" ref-type="bibr">49</xref>]. Predicted aligned error (PAE) plots are shown in <xref rid="SM1" ref-type="supplementary-material">Supplementary Figure S6</xref>.</p></sec><sec id="s4-18"><title>Hydrogen-deuterium exchange (HDX) mass spectrometry sample preparation</title><p>HDX reactions comparing apo CHK2 with CHK2 incubated with CaM were carried out in a 10 &#181;l reaction volume containing 10 pmol of full-length human CHK2 and 150 pmol of human CaM. Both proteins were recombinantly expressed (described above). The exchange reactions were initiated by the addition of 6.0 &#181;l of D<sub>2</sub>O buffer (20 mM HEPES pH 7.5, 200 mM NaCl, 2 mM CaCl<sub>2</sub>, 92.4% D<sub>2</sub>O (v/v)) to 4.0 &#181;l of protein (final D<sub>2</sub>O concentration of 55.5%). Reactions proceeded for 3 s, 30 s, 300 s and 3000 s at 20&#176;C before being quenched with ice-cold acidic quench buffer, resulting in a final concentration of 0.6M guanidine HCl and 0.9% formic acid post quench. All conditions and time points were created and run in independent triplicate. Samples were flash frozen immediately after quenching and stored at &#8722;80&#176;C.</p></sec><sec id="s4-19"><title>HDX protein digestion and MS/MS data collection</title><p>Protein samples were rapidly thawed and injected onto an integrated fluidics system containing a HDx-3 PAL liquid handling robot and climate-controlled (2&#176;C) chromatography system (LEAP Technologies), a Waters ACQUITY UPLC I-Class Series System, as well as an Impact HD QTOF Mass spectrometer (Bruker) using an established procedure [<xref rid="BCJ-2025-3431C50" ref-type="bibr">50</xref>]. The samples were run over an immobilised pepsin column (Affipro; AP-PC-001) at 200 &#181;l/min for 4 min at 2&#176;C. The resulting peptides were collected and desalted on a C18 trap column (ACQUITY UPLC BEH C18 1.7 &#181;m column, 2.1 mm &#215; 5 mm; Waters 186004629). The trap was subsequently eluted in line with an ACQUITY 300 &#197;, 1.7 &#181;m particle, 100 mm &#215; 2.1 mm C18 UPLC column (Waters; 186003686), using a gradient of 3&#8211;35% Buffer (Buffer A 0.1% formic acid; Buffer B 100% acetonitrile) over 11 min immediately followed by a gradient of 35&#8211;80% over 5 min. Mass spectrometry experiments acquired over a mass range from 150 to 2200 m/z using an electrospray ionisation source operated at a temperature of 200&#176;C and a spray voltage of 4.5 kV.</p></sec><sec id="s4-20"><title>HDX peptide identification</title><p>Peptides were identified from the non-deuterated samples of CHK2 using data-dependent acquisition following tandem MS/MS experiments (0.5 s precursor scan from 150 to 2000 m/z; twelve 0.25 s fragment scans from 150 to 2000 m/z). MS/MS datasets were analysed using FragPipe v19.1 and peptide identification was carried out by using a false discovery-based approach using a database of purified proteins and known contaminants [<xref rid="BCJ-2025-3431C51" ref-type="bibr">51</xref>,<xref rid="BCJ-2025-3431C52" ref-type="bibr">52</xref>]. MSFragger was utilised [<xref rid="BCJ-2025-3431C53" ref-type="bibr">53</xref>], and the precursor mass tolerance error was set to &#8722;20 to 20ppm. The fragment mass tolerance was set at 20 ppm. Protein digestion was set as nonspecific, searching between lengths of 4 and 50 aa, with a mass range of 400 to 5000 Da.</p></sec><sec id="s4-21"><title>HDX mass analysis of peptide centroids and measurement of deuterium incorporation</title><p>HD-Examiner Software (Sierra Analytics) was used to automatically calculate the level of deuterium incorporation into each peptide. All peptides were manually inspected for correct charge state, correct retention time, appropriate selection of isotopic distribution, etc. Deuteration levels were calculated using the centroid of the experimental isotope clusters. Results are presented as relative levels of deuterium incorporation and the only control for back exchange was the level of deuterium present in the buffer (55.5%). Differences in exchange in a peptide were considered significant if they met all three of the following criteria: &#8805;5% change in exchange, &#8805;0.40 Da difference in exchange, and a <italic toggle="yes">P</italic> value &lt; 0.01 using a two-tailed student <italic toggle="yes">t</italic>-test. Samples were only compared within a single experiment and were never compared with experiments completed at a different time with a different final D<sub>2</sub>O level. The data analysis statistics for all HDX-MS experiments are in <xref rid="SM1" ref-type="supplementary-material">Supplementary Table S2</xref> according to published guidelines [<xref rid="BCJ-2025-3431C54" ref-type="bibr">54</xref>]. All deuterium exchange incorporation data for all peptides at all time points is included in the Extended Data Excel file.</p></sec><sec id="s4-22"><title>Bioinformatic analysis</title><p>CHK2 homolog sequences were gathered using BlastP against the NRAA database, aligned with ClustalOmega [<xref rid="BCJ-2025-3431C55" ref-type="bibr">55</xref>] and visualised with Jalview [<xref rid="BCJ-2025-3431C56" ref-type="bibr">56</xref>]</p></sec><sec id="s4-23"><title>RPE cell culture</title><p>hTERT-immortalised RPE cells hTERT RPE-1 (ATCC, #CRL-4000) cells were maintained in DMEM/F12 (1:1) (Gibco, #11330&#8211;032) supplemented with 10% FBS (Bovogen, #SFBS-F) and 0.01 mg/ml hygromycin B (Roche, #10843555001) in an incubator at 37&#176;C and 10% CO2. Cells were passaged twice weekly.</p></sec><sec id="s4-24"><title>Generation and screening of CRISPR-edited cell lines</title><p>hTERT RPE cells were edited using CRISPR editing strategy described previously [<xref rid="BCJ-2025-3431C57" ref-type="bibr">57</xref>]. CHK2 guide RNA sequences were designed using the CRISPOR software package [<xref rid="BCJ-2025-3431C58" ref-type="bibr">58</xref>]. 20 bp guides beginning with G were selected. 5&#8242;-CACC-3&#8242; and 5&#8242;-AAAC-3&#8242; were appended to the sense and antisense guide sequences, respectively. Annealed gRNAs were cloned into the eSpCas9-hGeminin plasmid (Addgene plasmid, #86613). The resulting plasmid is referred to as eSpCas9-hGeminin &#8211;CHK2 gRNA. To generate the CHK2 K373A point mutation, a 200 bp single-stranded oligonucleotide (ssODN) donor was synthesised by IDT, which included lysine 373 to alanine mutation, silent mutations in the PAM (generates an AclI restriction site used for screening purposes) and in the corresponding gRNA sequence (to reduce re-editing).</p><p>For transfection, cells were harvested by trypsinisation at 80% confluency. 1 &#215; 10<sup>6</sup> cells were co-transfected with 5 &#181;g of eSpCas9-hGeminin &#8211;CHK2 gRNA plasmid, 5 &#181;g of ATP1A1_plasmid_donor_RD (Addgene plasmid, #86551), and 2.5 &#181;l ssODN donor (100 &#181;M). To generate control cell lines, 1 &#215; 10<sup>6</sup> cells were co-transfected with 5 &#181;g of eSpCas9-hGeminin plasmid (Addgene plasmid, #86613) and 5 ug of ATP1A1_plasmid_donor_RD (Addgene plasmid, #86551). Cells were electroporated using the Neon Transfection System (Invitrogen, #MPK5000) at 1350 V, 20 ms, 2 pulse. Electroporated cells were incubated in 15 cm round dishes for 72 h, then treated with 10 &#181;M ouabain (Sigma, #O3125) selection media, which was replaced every few days. To obtain single clones including the point mutations, following seven days of ouabain treatment, cells were trypsinised and limited dilutions were performed. Colonies in 96 wells were expanded to six-well plates for cryopreservation and DNA analysis.</p><p>Genomic DNA was isolated by using Genomic DNA purification kit (Sangon, #B618503). To screen cell lines for genome edits corresponding to CHK2 lysine 373, a 684 bp PCR product was amplified using the primer Forward: 5&#8242;- GAGACACTGGGGTCTAAGAACCATGTAG -3&#8242; and Reverse: 5&#8242;- GGTGGTGTGCATCTGTAGTCCCAG -3&#8242;. The PCR product was digested with AclI (New England BioLabs, #R0598S) to confirm insertion of the ssODN. To validate the point mutation, PCR products were sequenced using the forward primer 5&#8242;- GAGACACTGGGGTCTAAGAACCATGTAG -3&#8242; by Sanger Sequencing.</p></sec><sec id="s4-25"><title>Cell proliferation assays</title><p>For cell growth assays, hTERT-immortalised RPE cells were plated at 2000 cells per well (control cells) and 1000 cells per well (<italic toggle="yes">CHK2<sup>K373A</sup>
</italic>) in a 96-well plate and left to settle for 24 h before being transferred to an IncuCyte S3 instrument. Images were taken every 2 h for 72 h by phase contrast. Cell proliferation was then measured using IncuCyte S3 software (version 2022B). To examine differences in the presence of DNA damage, cells were stimulated at time 0 with Camptothecin (CPT; Sigma) at 10 and 100 nM prepared in DMSO. Cell confluency was measured as described above. GraphPad Prism was used for data analysis. Paired <italic toggle="yes">t</italic>-test or two-way ANOVA was used for calculating significance.</p></sec><sec id="s4-26"><title>Preparation of RPE cells for immunoblot</title><p>hTERT-immortalised RPE cells (wildtype and <italic toggle="yes">CHK2<sup>K373A</sup>
</italic>) were seeded into 12-well plates at 5 &#8201;&#215;&#8201; 10<sup>5</sup> cells/well overnight. Cells were harvested in ice-cold RIPA buffer [10 &#8201;mM Tris-HCl pH 8.0, 1 &#8201;mM EGTA, 2 &#8201;mM MgCl<sub>2</sub>, 0.5% v/v Triton X-100, 0.1% w/v Na deoxycholate, 0.5% w/v SDS and 90 &#8201;mM NaCl] supplemented with 1 x Protease &amp; Phosphatase Inhibitor Cocktail (Roche) and 100 &#8201;U/ml Denarase (c-LEcta).</p></sec></sec><sec sec-type="supplementary-material" id="ss6"><title>Supplementary material</title><supplementary-material id="SM1" position="float" content-type="local-data" orientation="portrait"><label>online supplementary material 1</label><media xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="bcj-482-23-BCJ20253431-s001.pdf" position="float" orientation="portrait"/></supplementary-material></sec></body><back><ack><title>Acknowledgments</title><p>We thank James Knox and the MiMo crew for facilitating vital discussions, and Meredith Jenkins for assistance with the HDX-MS experiments.</p></ack><sec sec-type="data-availability" id="s5"><title>Data Availability</title><p>Source data are published as an accompanying file; any additional data, including expression construct sequences, are available from the corresponding authors upon request. Any materials are available from the corresponding authors under Materials Transfer Agreement. Mass spectrometry data have been deposited to the ProteomeXchange Consortium via the PRIDE partner repository [59] with the dataset identifiers (PXD048473; PXD062332 and jPOST [60] JPST003727).</p></sec><sec sec-type="COI-statement" id="s6"><title>Competing Interests</title><p>J.E.B. reports personal fees from Scorpion Therapeutics and Reactive Therapeutics; and research contracts from Novartis and Calico Life Sciences. All other authors declare no competing interests.</p></sec><sec sec-type="funding" id="s7"><title>Funding</title><p>We thank the National Health and Medical Research Council of Australia for grant (CRH, 2034044; JWS, 2001817; JMM, 1172929 and 2034104; IRIISS) support, the Australian Research Council for grant support (JWS, DP210102840) and the Victorian State Government Operational Infrastructure Support Scheme. JEB is supported by the Natural Science and Engineering Research Council (Discovery Grant NSERC-2020-04241), Cancer Research Society (Operating Grant 1052949) and the Michael Smith Foundation for Health Research (Scholar award 17868).</p></sec><sec sec-type="open-access" id="s8"><title>Open Access</title><p>This article has been published open access under our Subscribe to Open programme, made possible through the support of our subscribing institutions, learn more here: <ext-link xmlns:xlink="http://www.w3.org/1999/xlink" xlink:href="https://portlandpress.com/pages/open_access_options_and_prices#conditional" ext-link-type="uri">https://portlandpress.com/pages/open_access_options_and_prices#conditional</ext-link>
</p></sec><sec sec-type="author-contribution" id="s9"><title>CRediT Author Contribution</title><p>C.R.H. designed, performed and analysed experiments; C.R.H. wrote the paper with J.M.M.; T.W. and J.P. generated the CRISPR-edited cell lines; S.N.Y., T.D., H.N., S.S., K.A.D., A.G.C., V.V., L.J.M., L.F.D., M.J.B., G.M., A.R.M. and J.E.B. performed and/or analysed experiments; J.W.S. and J.M.M. supervised the project, analysed and interpreted data; all authors commented on the manuscript.</p></sec><ref-list><title>References</title><ref id="BCJ-2025-3431C1"><label>1</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chin</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Means</surname><given-names>A.R</given-names></string-name></person-group><year>2000</year><article-title>Calmodulin: a prototypical calcium sensor</article-title><source>Trends Cell Biol.</source><volume>10</volume><fpage>322</fpage><lpage>328</lpage><pub-id pub-id-type="doi">10.1016/s0962-8924(00)01800-6</pub-id><pub-id pub-id-type="pmid">10884684</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C2"><label>2</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kahl</surname><given-names>C.R.</given-names></string-name><string-name name-style="western"><surname>Means</surname><given-names>A.R</given-names></string-name></person-group><year>2003</year><article-title>Regulation of cell cycle progression by calcium/calmodulin-dependent pathways</article-title><source>Endocr. Rev.</source><volume>24</volume><fpage>719</fpage><lpage>736</lpage><pub-id pub-id-type="doi">10.1210/er.2003-0008</pub-id><pub-id pub-id-type="pmid">14671000</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C3"><label>3</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Babu</surname><given-names>Y.S.</given-names></string-name><string-name name-style="western"><surname>Sack</surname><given-names>J.S.</given-names></string-name><string-name name-style="western"><surname>Greenhough</surname><given-names>T.J.</given-names></string-name><string-name name-style="western"><surname>Bugg</surname><given-names>C.E.</given-names></string-name><string-name name-style="western"><surname>Means</surname><given-names>A.R.</given-names></string-name><string-name name-style="western"><surname>Cook</surname><given-names>W.J</given-names></string-name></person-group><year>1985</year><article-title>Three-dimensional structure of calmodulin</article-title><source>Nature</source><volume>315</volume><fpage>37</fpage><lpage>40</lpage><pub-id pub-id-type="doi">10.1038/315037a0</pub-id><pub-id pub-id-type="pmid">3990807</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C4"><label>4</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Tanaka</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Ikura</surname><given-names>M</given-names></string-name></person-group><year>1995</year><article-title>Calcium-induced conformational transition revealed by the solution structure of apo calmodulin</article-title><source>Nat. Struct. Biol.</source><volume>2</volume><fpage>758</fpage><lpage>767</lpage><pub-id pub-id-type="doi">10.1038/nsb0995-758</pub-id><pub-id pub-id-type="pmid">7552747</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C5"><label>5</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tidow</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Nissen</surname><given-names>P</given-names></string-name></person-group><year>2013</year><article-title>Structural diversity of calmodulin binding to its target sites</article-title><source>FEBS J.</source><volume>280</volume><fpage>5551</fpage><lpage>5565</lpage><pub-id pub-id-type="doi">10.1111/febs.12296</pub-id><pub-id pub-id-type="pmid">23601118</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C6"><label>6</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Montigiani</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Neri</surname><given-names>G.</given-names></string-name><string-name name-style="western"><surname>Neri</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Neri</surname><given-names>D</given-names></string-name></person-group><year>1996</year><article-title>Alanine substitutions in calmodulin-binding peptides result in unexpected affinity enhancement</article-title><source>J. Mol. Biol.</source><volume>258</volume><fpage>6</fpage><lpage>13</lpage><pub-id pub-id-type="doi">10.1006/jmbi.1996.0229</pub-id><pub-id pub-id-type="pmid">8613992</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C7"><label>7</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shen</surname><given-names>X.</given-names></string-name><string-name name-style="western"><surname>Valencia</surname><given-names>C.A.</given-names></string-name><string-name name-style="western"><surname>Szostak</surname><given-names>J.W.</given-names></string-name><string-name name-style="western"><surname>Dong</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Liu</surname><given-names>R</given-names></string-name></person-group><year>2005</year><article-title>Scanning the human proteome for calmodulin-binding proteins</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>102</volume><fpage>5969</fpage><lpage>5974</lpage><pub-id pub-id-type="doi">10.1073/pnas.0407928102</pub-id><pub-id pub-id-type="pmid">15840729</pub-id><pub-id pub-id-type="pmcid">PMC1087907</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C8"><label>8</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yamniuk</surname><given-names>A.P.</given-names></string-name><string-name name-style="western"><surname>Vogel</surname><given-names>H.J</given-names></string-name></person-group><year>2004</year><article-title>Calmodulin&#8217;s flexibility allows for promiscuity in its interactions with target proteins and peptides</article-title><source>Mol. Biotechnol.</source><volume>27</volume><fpage>33</fpage><lpage>57</lpage><pub-id pub-id-type="doi">10.1385/MB:27:1:33</pub-id><pub-id pub-id-type="pmid">15122046</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C9"><label>9</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bayer</surname><given-names>K.U.</given-names></string-name><string-name name-style="western"><surname>Schulman</surname><given-names>H</given-names></string-name></person-group><year>2019</year><article-title>CaM Kinase: still Inspiring at 40</article-title><source>Neuron</source><volume>103</volume><fpage>380</fpage><lpage>394</lpage><pub-id pub-id-type="doi">10.1016/j.neuron.2019.05.033</pub-id><pub-id pub-id-type="pmid">31394063</pub-id><pub-id pub-id-type="pmcid">PMC6688632</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C10"><label>10</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Rellos</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Pike</surname><given-names>A.C.W.</given-names></string-name><string-name name-style="western"><surname>Niesen</surname><given-names>F.H.</given-names></string-name><string-name name-style="western"><surname>Salah</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Lee</surname><given-names>W.H.</given-names></string-name><string-name name-style="western"><surname>Von Delft</surname><given-names>F</given-names></string-name><etal>et al.</etal></person-group><year>2010</year><article-title>Structure of the CaMKIIdelta/calmodulin complex reveals the molecular mechanism of CaMKII kinase activation</article-title><source>PLoS Biol.</source><volume>8</volume><fpage>e1000426</fpage><pub-id pub-id-type="doi">10.1371/journal.pbio.1000426</pub-id><pub-id pub-id-type="pmid">20668654</pub-id><pub-id pub-id-type="pmcid">PMC2910593</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C11"><label>11</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kuper</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Bakalova</surname><given-names>N.</given-names></string-name><string-name name-style="western"><surname>Kursula</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Wilmanns</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>De Diego</surname><given-names>I</given-names></string-name></person-group><year>2010</year><article-title>Molecular basis of the death-associated protein kinase-calcium/calmodulin regulator complex</article-title><source>Sci. Signal.</source><volume>3</volume><fpage>ra6</fpage><pub-id pub-id-type="doi">10.1126/scisignal.2000552</pub-id><pub-id pub-id-type="pmid">20103772</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C12"><label>12</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Simon</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Huart</surname><given-names>A.-S.</given-names></string-name><string-name name-style="western"><surname>Temmerman</surname><given-names>K.</given-names></string-name><string-name name-style="western"><surname>Vahokoski</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Mertens</surname><given-names>H.D.T.</given-names></string-name><string-name name-style="western"><surname>Komadina</surname><given-names>D</given-names></string-name><etal>et al.</etal></person-group><year>2016</year><article-title>Death-associated protein kinase activity is regulated by coupled calcium/calmodulin binding to two distinct sites</article-title><source>Structure</source><volume>24</volume><fpage>851</fpage><lpage>861</lpage><pub-id pub-id-type="doi">10.1016/j.str.2016.03.020</pub-id><pub-id pub-id-type="pmid">27133022</pub-id><pub-id pub-id-type="pmcid">PMC4906247</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C13"><label>13</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Komolov</surname><given-names>K.E.</given-names></string-name><string-name name-style="western"><surname>Sulon</surname><given-names>S.M.</given-names></string-name><string-name name-style="western"><surname>Bhardwaj</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Van Keulen</surname><given-names>S.C.</given-names></string-name><string-name name-style="western"><surname>Duc</surname><given-names>N.M.</given-names></string-name><string-name name-style="western"><surname>Laurinavichyute</surname><given-names>D.K</given-names></string-name><etal>et al.</etal></person-group><year>2021</year><article-title>Structure of a GRK5-Calmodulin Complex Reveals Molecular Mechanism of GRK Activation and Substrate Targeting</article-title><source>Mol. Cell</source><volume>81</volume><fpage>323</fpage><lpage>339</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2020.11.026</pub-id><pub-id pub-id-type="pmid">33321095</pub-id><pub-id pub-id-type="pmcid">PMC7855534</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C14"><label>14</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hudmon</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Schulman</surname><given-names>H</given-names></string-name></person-group><year>2002</year><article-title>Neuronal CA2+/calmodulin-dependent protein kinase II: the role of structure and autoregulation in cellular function</article-title><source>Annu. Rev. Biochem.</source><volume>71</volume><fpage>473</fpage><lpage>510</lpage><pub-id pub-id-type="doi">10.1146/annurev.biochem.71.110601.135410</pub-id><pub-id pub-id-type="pmid">12045104</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C15"><label>15</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Horne</surname><given-names>C.R.</given-names></string-name><string-name name-style="western"><surname>Dite</surname><given-names>T.A.</given-names></string-name><string-name name-style="western"><surname>Young</surname><given-names>S.N.</given-names></string-name><string-name name-style="western"><surname>Mather</surname><given-names>L.J.</given-names></string-name><string-name name-style="western"><surname>Dagley</surname><given-names>L.F.</given-names></string-name><string-name name-style="western"><surname>Johnson</surname><given-names>J.L.</given-names></string-name><etal>et al.</etal></person-group><year>2025</year><article-title>PSKH1 kinase activity is differentially modulated via allosteric binding of Ca<sup>2+</sup> sensor proteins</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>122</volume><fpage>e2420961122</fpage><pub-id pub-id-type="doi">10.1073/pnas.2420961122</pub-id><pub-id pub-id-type="pmid">39964718</pub-id><pub-id pub-id-type="pmcid">PMC11873932</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C16"><label>16</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Reinhardt</surname><given-names>H.C.</given-names></string-name><string-name name-style="western"><surname>Yaffe</surname><given-names>M.B</given-names></string-name></person-group><year>2009</year><article-title>Kinases that control the cell cycle in response to DNA damage: Chk1, Chk2, and MK2</article-title><source>Curr. Opin. Cell Biol.</source><volume>21</volume><fpage>245</fpage><lpage>255</lpage><pub-id pub-id-type="doi">10.1016/j.ceb.2009.01.018</pub-id><pub-id pub-id-type="pmid">19230643</pub-id><pub-id pub-id-type="pmcid">PMC2699687</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C17"><label>17</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Ahn</surname><given-names>J.Y.</given-names></string-name><string-name name-style="western"><surname>Schwarz</surname><given-names>J.K.</given-names></string-name><string-name name-style="western"><surname>Piwnica-Worms</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Canman</surname><given-names>C.E</given-names></string-name></person-group><year>2000</year><article-title>Threonine 68 phosphorylation by ataxia telangiectasia mutated is required for efficient activation of Chk2 in response to ionizing radiation</article-title><source>Cancer Res.</source><volume>60</volume><fpage>5934</fpage><lpage>5936</lpage><pub-id pub-id-type="pmid">11085506</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C18"><label>18</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Melchionna</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Chen</surname><given-names>X.B.</given-names></string-name><string-name name-style="western"><surname>Blasina</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>McGowan</surname><given-names>C.H</given-names></string-name></person-group><year>2000</year><article-title>Threonine 68 is required for radiation-induced phosphorylation and activation of Cds1</article-title><source>Nat. Cell Biol.</source><volume>2</volume><fpage>762</fpage><lpage>765</lpage><pub-id pub-id-type="doi">10.1038/35036406</pub-id><pub-id pub-id-type="pmid">11025670</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C19"><label>19</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cai</surname><given-names>Z.</given-names></string-name><string-name name-style="western"><surname>Chehab</surname><given-names>N.H.</given-names></string-name><string-name name-style="western"><surname>Pavletich</surname><given-names>N.P</given-names></string-name></person-group><year>2009</year><article-title>Structure and activation mechanism of the CHK2 DNA damage checkpoint kinase</article-title><source>Mol. Cell</source><volume>35</volume><fpage>818</fpage><lpage>829</lpage><pub-id pub-id-type="doi">10.1016/j.molcel.2009.09.007</pub-id><pub-id pub-id-type="pmid">19782031</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C20"><label>20</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lee</surname><given-names>C.H.</given-names></string-name><string-name name-style="western"><surname>Chung</surname><given-names>J.H</given-names></string-name></person-group><year>2001</year><article-title>The hCds1 (Chk2)-FHA domain is essential for a chain of phosphorylation events on hCds1 that is induced by ionizing radiation</article-title><source>J. Biol. Chem.</source><volume>276</volume><fpage>30537</fpage><lpage>30541</lpage><pub-id pub-id-type="doi">10.1074/jbc.M104414200</pub-id><pub-id pub-id-type="pmid">11390408</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C21"><label>21</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Cho</surname><given-names>D.-H.</given-names></string-name><string-name name-style="western"><surname>Lee</surname><given-names>H.-J.</given-names></string-name><string-name name-style="western"><surname>Lee</surname><given-names>J.Y.</given-names></string-name><string-name name-style="western"><surname>Park</surname><given-names>J.-H.</given-names></string-name><string-name name-style="western"><surname>Jo</surname><given-names>I</given-names></string-name></person-group><year>2021</year><article-title>Far-infrared irradiation inhibits breast cancer cell proliferation independently of DNA damage through increased nuclear Ca2+/calmodulin binding modulated-activation of checkpoint kinase 2</article-title><source>Journal of Photochemistry and Photobiology B: Biology</source><volume>219</volume><fpage>112188</fpage><pub-id pub-id-type="doi">10.1016/j.jphotobiol.2021.112188</pub-id><pub-id pub-id-type="pmid">33901880</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C22"><label>22</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Anderson</surname><given-names>K.A.</given-names></string-name><string-name name-style="western"><surname>Means</surname><given-names>R.L.</given-names></string-name><string-name name-style="western"><surname>Huang</surname><given-names>Q.H.</given-names></string-name><string-name name-style="western"><surname>Kemp</surname><given-names>B.E.</given-names></string-name><string-name name-style="western"><surname>Goldstein</surname><given-names>E.G.</given-names></string-name><string-name name-style="western"><surname>Selbert</surname><given-names>M.A.</given-names></string-name><etal>et al.</etal></person-group><year>1998</year><article-title>Components of a calmodulin-dependent protein kinase cascade. Molecular cloning, functional characterization and cellular localization of Ca2+/calmodulin-dependent protein kinase kinase beta</article-title><source>J. Biol. Chem.</source><volume>273</volume><fpage>31880</fpage><lpage>31889</lpage><pub-id pub-id-type="doi">10.1074/jbc.273.48.31880</pub-id><pub-id pub-id-type="pmid">9822657</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C23"><label>23</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Masson</surname><given-names>G.R.</given-names></string-name><string-name name-style="western"><surname>Jenkins</surname><given-names>M.L.</given-names></string-name><string-name name-style="western"><surname>Burke</surname><given-names>J.E</given-names></string-name></person-group><year>2017</year><article-title>An overview of hydrogen deuterium exchange mass spectrometry (HDX-MS) in drug discovery</article-title><source>Expert Opin. Drug Discov.</source><volume>12</volume><fpage>981</fpage><lpage>994</lpage><pub-id pub-id-type="doi">10.1080/17460441.2017.1363734</pub-id><pub-id pub-id-type="pmid">28770632</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C24"><label>24</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Anderson</surname><given-names>J.W.</given-names></string-name><string-name name-style="western"><surname>Vaisar</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Jones</surname><given-names>D.N.</given-names></string-name><string-name name-style="western"><surname>Pegram</surname><given-names>L.M.</given-names></string-name><string-name name-style="western"><surname>Vigers</surname><given-names>G.P.</given-names></string-name><string-name name-style="western"><surname>Chen</surname><given-names>H.</given-names></string-name><etal>et al.</etal></person-group><year>2024</year><article-title>Conformation selection by ATP-competitive inhibitors and allosteric communication in ERK2</article-title><source>Elife</source><volume>12</volume><fpage>RP91507</fpage><pub-id pub-id-type="doi">10.7554/eLife.91507</pub-id><pub-id pub-id-type="pmid">38537148</pub-id><pub-id pub-id-type="pmcid">PMC10972564</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C25"><label>25</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Lin</surname><given-names>D.Y.-W.</given-names></string-name><string-name name-style="western"><surname>Kueffer</surname><given-names>L.E.</given-names></string-name><string-name name-style="western"><surname>Juneja</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Wales</surname><given-names>T.E.</given-names></string-name><string-name name-style="western"><surname>Engen</surname><given-names>J.R.</given-names></string-name><string-name name-style="western"><surname>Andreotti</surname><given-names>A.H</given-names></string-name></person-group><year>2024</year><article-title>Conformational heterogeneity of the BTK PHTH domain drives multiple regulatory states</article-title><source>Elife</source><volume>12</volume><fpage>RP89489</fpage><pub-id pub-id-type="doi">10.7554/eLife.89489</pub-id><pub-id pub-id-type="pmid">38189455</pub-id><pub-id pub-id-type="pmcid">PMC10945472</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C26"><label>26</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Shaw</surname><given-names>A.L.</given-names></string-name><string-name name-style="western"><surname>Parson</surname><given-names>M.A.H.</given-names></string-name><string-name name-style="western"><surname>Truebestein</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Jenkins</surname><given-names>M.L.</given-names></string-name><string-name name-style="western"><surname>Leonard</surname><given-names>T.A.</given-names></string-name><string-name name-style="western"><surname>Burke</surname><given-names>J.E</given-names></string-name></person-group><year>2023</year><article-title>ATP-competitive and allosteric inhibitors induce differential conformational changes at the autoinhibitory interface of Akt1</article-title><source>Structure</source><volume>31</volume><fpage>343</fpage><lpage>354</lpage><pub-id pub-id-type="doi">10.1016/j.str.2023.01.007</pub-id><pub-id pub-id-type="pmid">36758543</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C27"><label>27</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Bodnar</surname><given-names>A.G.</given-names></string-name><string-name name-style="western"><surname>Ouellette</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Frolkis</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Holt</surname><given-names>S.E.</given-names></string-name><string-name name-style="western"><surname>Chiu</surname><given-names>C.P.</given-names></string-name><string-name name-style="western"><surname>Morin</surname><given-names>G.B.</given-names></string-name><etal>et al.</etal></person-group><year>1998</year><article-title>Extension of life-span by introduction of telomerase into normal human cells</article-title><source>Science</source><volume>279</volume><fpage>349</fpage><lpage>352</lpage><pub-id pub-id-type="doi">10.1126/science.279.5349.349</pub-id><pub-id pub-id-type="pmid">9454332</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C28"><label>28</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Scott</surname><given-names>S.J.</given-names></string-name><string-name name-style="western"><surname>Suvarna</surname><given-names>K.S.</given-names></string-name><string-name name-style="western"><surname>D&#8217;Avino</surname><given-names>P.P</given-names></string-name></person-group><year>2020</year><article-title>Synchronization of human retinal pigment epithelial-1 cells in mitosis</article-title><source>J. Cell. Sci.</source><volume>133</volume><fpage>jcs247940</fpage><pub-id pub-id-type="doi">10.1242/jcs.247940</pub-id><pub-id pub-id-type="pmid">32878943</pub-id><pub-id pub-id-type="pmcid">PMC7520456</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C29"><label>29</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Liu</surname><given-names>L.F.</given-names></string-name><string-name name-style="western"><surname>Desai</surname><given-names>S.D.</given-names></string-name><string-name name-style="western"><surname>Li</surname><given-names>T.K.</given-names></string-name><string-name name-style="western"><surname>Mao</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Sun</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Sim</surname><given-names>S.P</given-names></string-name></person-group><year>2000</year><article-title>Mechanism of action of camptothecin</article-title><source>Ann. N. Y. Acad. Sci.</source><volume>922</volume><fpage>1</fpage><lpage>10</lpage><pub-id pub-id-type="doi">10.1111/j.1749-6632.2000.tb07020.x</pub-id><pub-id pub-id-type="pmid">11193884</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C30"><label>30</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Ji</surname><given-names>W.</given-names></string-name><string-name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Gao</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Li</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Cai</surname><given-names>H.</given-names></string-name><etal>et al.</etal></person-group><year>2010</year><article-title>GsCBRLK, a calcium/calmodulin-binding receptor-like kinase, is a positive regulator of plant tolerance to salt and ABA stress</article-title><source>J. Exp. Bot.</source><volume>61</volume><fpage>2519</fpage><lpage>2533</lpage><pub-id pub-id-type="doi">10.1093/jxb/erq084</pub-id><pub-id pub-id-type="pmid">20400529</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C31"><label>31</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Chaudhuri</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Yang</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Chen</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Poovaiah</surname><given-names>B.W</given-names></string-name></person-group><year>2004</year><article-title>Calcium/calmodulin up-regulates a cytoplasmic receptor-like kinase in plants</article-title><source>J. Biol. Chem.</source><volume>279</volume><fpage>42552</fpage><lpage>42559</lpage><pub-id pub-id-type="doi">10.1074/jbc.M402830200</pub-id><pub-id pub-id-type="pmid">15292241</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C32"><label>32</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Yang</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Chaudhuri</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Yang</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Du</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Poovaiah</surname><given-names>B.W</given-names></string-name></person-group><year>2010</year><article-title>A calcium/calmodulin-regulated member of the receptor-like kinase family confers cold tolerance in plants</article-title><source>J. Biol. Chem.</source><volume>285</volume><fpage>7119</fpage><lpage>7126</lpage><pub-id pub-id-type="doi">10.1074/jbc.M109.035659</pub-id><pub-id pub-id-type="pmid">20026608</pub-id><pub-id pub-id-type="pmcid">PMC2844161</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C33"><label>33</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chaturvedi</surname><given-names>P.</given-names></string-name><string-name name-style="western"><surname>Eng</surname><given-names>W.K.</given-names></string-name><string-name name-style="western"><surname>Zhu</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Mattern</surname><given-names>M.R.</given-names></string-name><string-name name-style="western"><surname>Mishra</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Hurle</surname><given-names>M.R.</given-names></string-name><etal>et al.</etal></person-group><year>1999</year><article-title>Mammalian Chk2 is a downstream effector of the ATM-dependent DNA damage checkpoint pathway</article-title><source>Oncogene</source><volume>18</volume><fpage>4047</fpage><lpage>4054</lpage><pub-id pub-id-type="doi">10.1038/sj.onc.1202925</pub-id><pub-id pub-id-type="pmid">10435585</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C34"><label>34</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Pereg</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Lam</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Teunisse</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Biton</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Meulmeester</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Mittelman</surname><given-names>L.</given-names></string-name><etal>et al.</etal></person-group><year>2006</year><article-title>Differential roles of ATM- and Chk2-mediated phosphorylations of Hdmx in response to DNA damage</article-title><source>Mol. Cell. Biol.</source><volume>26</volume><fpage>6819</fpage><lpage>6831</lpage><pub-id pub-id-type="doi">10.1128/MCB.00562-06</pub-id><pub-id pub-id-type="pmid">16943424</pub-id><pub-id pub-id-type="pmcid">PMC1592859</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C35"><label>35</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zannini</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Delia</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Buscemi</surname><given-names>G</given-names></string-name></person-group><year>2014</year><article-title>CHK2 kinase in the DNA damage response and beyond</article-title><source>J. Mol. Cell Biol.</source><volume>6</volume><fpage>442</fpage><lpage>457</lpage><pub-id pub-id-type="doi">10.1093/jmcb/mju045</pub-id><pub-id pub-id-type="pmid">25404613</pub-id><pub-id pub-id-type="pmcid">PMC4296918</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C36"><label>36</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Zhang</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Willers</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Feng</surname><given-names>Z.</given-names></string-name><string-name name-style="western"><surname>Ghosh</surname><given-names>J.C.</given-names></string-name><string-name name-style="western"><surname>Kim</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Weaver</surname><given-names>D.T.</given-names></string-name><etal>et al.</etal></person-group><year>2004</year><article-title>Chk2 phosphorylation of BRCA1 regulates DNA double-strand break repair</article-title><source>Mol. Cell. Biol.</source><volume>24</volume><fpage>708</fpage><lpage>718</lpage><pub-id pub-id-type="doi">10.1128/MCB.24.2.708-718.2004</pub-id><pub-id pub-id-type="pmid">14701743</pub-id><pub-id pub-id-type="pmcid">PMC343805</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C37"><label>37</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fujimoto</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Onishi</surname><given-names>N.</given-names></string-name><string-name name-style="western"><surname>Kato</surname><given-names>N.</given-names></string-name><string-name name-style="western"><surname>Takekawa</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Xu</surname><given-names>X.Z.</given-names></string-name><string-name name-style="western"><surname>Kosugi</surname><given-names>A.</given-names></string-name><etal>et al.</etal></person-group><year>2006</year><article-title>Regulation of the antioncogenic Chk2 kinase by the oncogenic Wip1 phosphatase</article-title><source>Cell Death Differ.</source><volume>13</volume><fpage>1170</fpage><lpage>1180</lpage><pub-id pub-id-type="doi">10.1038/sj.cdd.4401801</pub-id><pub-id pub-id-type="pmid">16311512</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C38"><label>38</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Hoffman</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Carpenter</surname><given-names>H.</given-names></string-name><string-name name-style="western"><surname>Kahl</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Watt</surname><given-names>L.F.</given-names></string-name><string-name name-style="western"><surname>Dickson</surname><given-names>P.W.</given-names></string-name><string-name name-style="western"><surname>Rostas</surname><given-names>J.A.P</given-names></string-name><etal>et al.</etal></person-group><year>2014</year><article-title>Dephosphorylation of CaMKII at T253 controls the metaphase-anaphase transition</article-title><source>Cell. Signal</source><volume>26</volume><fpage>748</fpage><lpage>756</lpage><pub-id pub-id-type="doi">10.1016/j.cellsig.2013.12.015</pub-id><pub-id pub-id-type="pmid">24407174</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C39"><label>39</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kornev</surname><given-names>A.P.</given-names></string-name><string-name name-style="western"><surname>Haste</surname><given-names>N.M.</given-names></string-name><string-name name-style="western"><surname>Taylor</surname><given-names>S.S.</given-names></string-name><string-name name-style="western"><surname>Eyck</surname><given-names>L.F.T</given-names></string-name></person-group><year>2006</year><article-title>Surface comparison of active and inactive protein kinases identifies a conserved activation mechanism</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>103</volume><fpage>17783</fpage><lpage>17788</lpage><pub-id pub-id-type="doi">10.1073/pnas.0607656103</pub-id><pub-id pub-id-type="pmid">17095602</pub-id><pub-id pub-id-type="pmcid">PMC1693824</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C40"><label>40</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Tanzer</surname><given-names>M.C.</given-names></string-name><string-name name-style="western"><surname>Matti</surname><given-names>I.</given-names></string-name><string-name name-style="western"><surname>Hildebrand</surname><given-names>J.M.</given-names></string-name><string-name name-style="western"><surname>Young</surname><given-names>S.N.</given-names></string-name><string-name name-style="western"><surname>Wardak</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Tripaydonis</surname><given-names>A.</given-names></string-name><etal>et al.</etal></person-group><year>2016</year><article-title>Evolutionary divergence of the necroptosis effector MLKL</article-title><source>Cell Death Differ.</source><volume>23</volume><fpage>1185</fpage><lpage>1197</lpage><pub-id pub-id-type="doi">10.1038/cdd.2015.169</pub-id><pub-id pub-id-type="pmid">26868910</pub-id><pub-id pub-id-type="pmcid">PMC4946887</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C41"><label>41</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Garnish</surname><given-names>S.E.</given-names></string-name><string-name name-style="western"><surname>Meng</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Koide</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Sandow</surname><given-names>J.J.</given-names></string-name><string-name name-style="western"><surname>Denbaum</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Jacobsen</surname><given-names>A.V.</given-names></string-name><etal>et al.</etal></person-group><year>2021</year><article-title>Conformational interconversion of MLKL and disengagement from RIPK3 precede cell death by necroptosis</article-title><source>Nat. Commun.</source><volume>12</volume><fpage>2211</fpage><fpage>2211</fpage><pub-id pub-id-type="doi">10.1038/s41467-021-22400-z</pub-id><pub-id pub-id-type="pmid">33850121</pub-id><pub-id pub-id-type="pmcid">PMC8044208</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C42"><label>42</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Fitzgibbon</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Meng</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Murphy</surname><given-names>J.M</given-names></string-name></person-group><year>2022</year><article-title>Co-expression of recombinant RIPK3:MLKL complexes using the baculovirus-insect cell system</article-title><source>Meth. Enzymol</source><volume>667</volume><fpage>183</fpage><lpage>227</lpage><pub-id pub-id-type="doi">10.1016/bs.mie.2022.03.029</pub-id><pub-id pub-id-type="pmid">35525542</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C43"><label>43</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Petrie</surname><given-names>E.J.</given-names></string-name><string-name name-style="western"><surname>Birkinshaw</surname><given-names>R.W.</given-names></string-name><string-name name-style="western"><surname>Koide</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Denbaum</surname><given-names>E.</given-names></string-name><string-name name-style="western"><surname>Hildebrand</surname><given-names>J.M.</given-names></string-name><string-name name-style="western"><surname>Garnish</surname><given-names>S.E.</given-names></string-name><etal>et al.</etal></person-group><year>2020</year><article-title>Identification of MLKL membrane translocation as a checkpoint in necroptotic cell death using Monobodies</article-title><source>Proc. Natl. Acad. Sci. U.S.A.</source><volume>117</volume><fpage>8468</fpage><lpage>8475</lpage><pub-id pub-id-type="doi">10.1073/pnas.1919960117</pub-id><pub-id pub-id-type="pmid">32234780</pub-id><pub-id pub-id-type="pmcid">PMC7165463</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C44"><label>44</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Murphy</surname><given-names>J.M.</given-names></string-name><string-name name-style="western"><surname>Zhang</surname><given-names>Q.</given-names></string-name><string-name name-style="western"><surname>Young</surname><given-names>S.N.</given-names></string-name><string-name name-style="western"><surname>Reese</surname><given-names>M.L.</given-names></string-name><string-name name-style="western"><surname>Bailey</surname><given-names>F.P.</given-names></string-name><string-name name-style="western"><surname>Eyers</surname><given-names>P.A.</given-names></string-name><etal>et al.</etal></person-group><year>2014</year><article-title>A robust methodology to subclassify pseudokinases based on their nucleotide-binding properties</article-title><source>Biochem. J.</source><volume>457</volume><fpage>323</fpage><lpage>334</lpage><pub-id pub-id-type="doi">10.1042/BJ20131174</pub-id><pub-id pub-id-type="pmid">24107129</pub-id><pub-id pub-id-type="pmcid">PMC5679212</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C45"><label>45</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Chambers</surname><given-names>M.C.</given-names></string-name><string-name name-style="western"><surname>Maclean</surname><given-names>B.</given-names></string-name><string-name name-style="western"><surname>Burke</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Amodei</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Ruderman</surname><given-names>D.L.</given-names></string-name><string-name name-style="western"><surname>Neumann</surname><given-names>S.</given-names></string-name><etal>et al.</etal></person-group><year>2012</year><article-title>A cross-platform toolkit for mass spectrometry and proteomics</article-title><source>Nat. Biotechnol.</source><volume>30</volume><fpage>918</fpage><lpage>920</lpage><pub-id pub-id-type="doi">10.1038/nbt.2377</pub-id><pub-id pub-id-type="pmid">23051804</pub-id><pub-id pub-id-type="pmcid">PMC3471674</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C46"><label>46</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>G&#246;tze</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Iacobucci</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Ihling</surname><given-names>C.H.</given-names></string-name><string-name name-style="western"><surname>Sinz</surname><given-names>A</given-names></string-name></person-group><year>2019</year><article-title>A simple cross-linking/mass spectrometry workflow for studying system-wide protein interactions</article-title><source>Anal. Chem.</source><volume>91</volume><fpage>10236</fpage><lpage>10244</lpage><pub-id pub-id-type="doi">10.1021/acs.analchem.9b02372</pub-id><pub-id pub-id-type="pmid">31283178</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C47"><label>47</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Mendes</surname><given-names>M.L.</given-names></string-name><string-name name-style="western"><surname>Fischer</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Chen</surname><given-names>Z.A.</given-names></string-name><string-name name-style="western"><surname>Barbon</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>O&#8217;Reilly</surname><given-names>F.J.</given-names></string-name><string-name name-style="western"><surname>Giese</surname><given-names>S.H.</given-names></string-name><etal>et al.</etal></person-group><year>2019</year><article-title>An integrated workflow for crosslinking mass spectrometry</article-title><source>Mol. Syst. Biol.</source><volume>15</volume><fpage>e8994</fpage><pub-id pub-id-type="doi">10.15252/msb.20198994</pub-id><pub-id pub-id-type="pmid">31556486</pub-id><pub-id pub-id-type="pmcid">PMC6753376</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C48"><label>48</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Combe</surname><given-names>C.W.</given-names></string-name><string-name name-style="western"><surname>Graham</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Kolbowski</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Fischer</surname><given-names>L.</given-names></string-name><string-name name-style="western"><surname>Rappsilber</surname><given-names>J</given-names></string-name></person-group><year>2024</year><article-title>xiVIEW: Visualisation of Crosslinking Mass Spectrometry Data</article-title><source>J. Mol. Biol</source><volume>436</volume><fpage>168656</fpage><pub-id pub-id-type="doi">10.1016/j.jmb.2024.168656</pub-id><pub-id pub-id-type="pmid">39237202</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C49"><label>49</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Jumper</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Evans</surname><given-names>R.</given-names></string-name><string-name name-style="western"><surname>Pritzel</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Green</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Figurnov</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Ronneberger</surname><given-names>O.</given-names></string-name><etal>et al.</etal></person-group><year>2021</year><article-title>Highly accurate protein structure prediction with AlphaFold</article-title><source>Nature</source><volume>596</volume><fpage>583</fpage><lpage>589</lpage><pub-id pub-id-type="doi">10.1038/s41586-021-03819-2</pub-id><pub-id pub-id-type="pmid">34265844</pub-id><pub-id pub-id-type="pmcid">PMC8371605</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C50"><label>50</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Stariha</surname><given-names>J.T.B.</given-names></string-name><string-name name-style="western"><surname>Hoffmann</surname><given-names>R.M.</given-names></string-name><string-name name-style="western"><surname>Hamelin</surname><given-names>D.J.</given-names></string-name><string-name name-style="western"><surname>Burke</surname><given-names>J.E</given-names></string-name></person-group><year>2021</year><article-title>Probing protein-membrane interactions and dynamics using hydrogen-deuterium exchange mass spectrometry (HDX-MS)</article-title><source>Methods Mol. Biol.</source><volume>2263</volume><fpage>465</fpage><lpage>485</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-1197-5_22</pub-id><pub-id pub-id-type="pmid">33877613</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C51"><label>51</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Dobbs</surname><given-names>J.M.</given-names></string-name><string-name name-style="western"><surname>Jenkins</surname><given-names>M.L.</given-names></string-name><string-name name-style="western"><surname>Burke</surname><given-names>J.E</given-names></string-name></person-group><year>2020</year><article-title>
<italic toggle="yes">Escherichia coli</italic> and Sf9 contaminant databases to increase efficiency of tandem mass spectrometry peptide identification in structural mass spectrometry experiments</article-title><source>J. Am. Soc. Mass Spectrom.</source><volume>31</volume><fpage>2202</fpage><lpage>2209</lpage><pub-id pub-id-type="doi">10.1021/jasms.0c00283</pub-id><pub-id pub-id-type="pmid">32869988</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C52"><label>52</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Da Veiga Leprevost</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Haynes</surname><given-names>S.E.</given-names></string-name><string-name name-style="western"><surname>Avtonomov</surname><given-names>D.M.</given-names></string-name><string-name name-style="western"><surname>Chang</surname><given-names>H.Y.</given-names></string-name><string-name name-style="western"><surname>Shanmugam</surname><given-names>A.K.</given-names></string-name><string-name name-style="western"><surname>Mellacheruvu</surname><given-names>D</given-names></string-name><etal>et al.</etal></person-group><year>2020</year><article-title>Philosopher: a versatile toolkit for shotgun proteomics data analysis</article-title><source>Nat. Methods</source><volume>17</volume><fpage>869</fpage><lpage>870</lpage><pub-id pub-id-type="doi">10.1038/s41592-020-0912-y</pub-id><pub-id pub-id-type="pmid">32669682</pub-id><pub-id pub-id-type="pmcid">PMC7509848</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C53"><label>53</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Kong</surname><given-names>A.T.</given-names></string-name><string-name name-style="western"><surname>Leprevost</surname><given-names>F.V.</given-names></string-name><string-name name-style="western"><surname>Avtonomov</surname><given-names>D.M.</given-names></string-name><string-name name-style="western"><surname>Mellacheruvu</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Nesvizhskii</surname><given-names>A.I</given-names></string-name></person-group><year>2017</year><article-title>MSFragger: ultrafast and comprehensive peptide identification in mass spectrometry-based proteomics</article-title><source>Nat. Methods</source><volume>14</volume><fpage>513</fpage><lpage>520</lpage><pub-id pub-id-type="doi">10.1038/nmeth.4256</pub-id><pub-id pub-id-type="pmid">28394336</pub-id><pub-id pub-id-type="pmcid">PMC5409104</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C54"><label>54</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Masson</surname><given-names>G.R.</given-names></string-name><string-name name-style="western"><surname>Burke</surname><given-names>J.E.</given-names></string-name><string-name name-style="western"><surname>Ahn</surname><given-names>N.G.</given-names></string-name><string-name name-style="western"><surname>Anand</surname><given-names>G.S.</given-names></string-name><string-name name-style="western"><surname>Borchers</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Brier</surname><given-names>S.</given-names></string-name><etal>et al.</etal></person-group><year>2019</year><article-title>Recommendations for performing, interpreting and reporting hydrogen deuterium exchange mass spectrometry (HDX-MS) experiments</article-title><source>Nat. Methods</source><volume>16</volume><fpage>595</fpage><lpage>602</lpage><pub-id pub-id-type="doi">10.1038/s41592-019-0459-y</pub-id><pub-id pub-id-type="pmid">31249422</pub-id><pub-id pub-id-type="pmcid">PMC6614034</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C55"><label>55</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Sievers</surname><given-names>F.</given-names></string-name><string-name name-style="western"><surname>Higgins</surname><given-names>D.G</given-names></string-name></person-group><year>2021</year><article-title>The clustal omega multiple alignment package</article-title><source>Methods Mol. Biol.</source><volume>2231</volume><fpage>3</fpage><lpage>16</lpage><pub-id pub-id-type="doi">10.1007/978-1-0716-1036-7_1</pub-id><pub-id pub-id-type="pmid">33289883</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C56"><label>56</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Waterhouse</surname><given-names>A.M.</given-names></string-name><string-name name-style="western"><surname>Procter</surname><given-names>J.B.</given-names></string-name><string-name name-style="western"><surname>Martin</surname><given-names>D.M.A.</given-names></string-name><string-name name-style="western"><surname>Clamp</surname><given-names>M.</given-names></string-name><string-name name-style="western"><surname>Barton</surname><given-names>G.J</given-names></string-name></person-group><year>2009</year><article-title>Jalview Version 2--a multiple sequence alignment editor and analysis workbench</article-title><source>Bioinformatics</source><volume>25</volume><fpage>1189</fpage><lpage>1191</lpage><pub-id pub-id-type="doi">10.1093/bioinformatics/btp033</pub-id><pub-id pub-id-type="pmid">19151095</pub-id><pub-id pub-id-type="pmcid">PMC2672624</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C57"><label>57</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Morrison</surname><given-names>K.R.</given-names></string-name><string-name name-style="western"><surname>Wang</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Chan</surname><given-names>K.Y.</given-names></string-name><string-name name-style="western"><surname>Trotter</surname><given-names>E.W.</given-names></string-name><string-name name-style="western"><surname>Gillespie</surname><given-names>A.</given-names></string-name><string-name name-style="western"><surname>Michael</surname><given-names>M.Z.</given-names></string-name><etal>et al.</etal></person-group><year>2023</year><article-title>Elevated basal AMP-activated protein kinase activity sensitizes colorectal cancer cells to growth inhibition by metformin</article-title><source>Open Biol.</source><volume>13</volume><fpage>230021</fpage><pub-id pub-id-type="doi">10.1098/rsob.230021</pub-id><pub-id pub-id-type="pmid">37042113</pub-id><pub-id pub-id-type="pmcid">PMC10090877</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C58"><label>58</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Concordet</surname><given-names>J.-P.</given-names></string-name><string-name name-style="western"><surname>Haeussler</surname><given-names>M</given-names></string-name></person-group><year>2018</year><article-title>CRISPOR: intuitive guide selection for CRISPR/Cas9 genome editing experiments and screens</article-title><source>Nucleic Acids Res.</source><volume>46</volume><fpage>W242</fpage><lpage>W245</lpage><pub-id pub-id-type="doi">10.1093/nar/gky354</pub-id><pub-id pub-id-type="pmid">29762716</pub-id><pub-id pub-id-type="pmcid">PMC6030908</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C59"><label>59</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Perez-Riverol</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Bai</surname><given-names>J.</given-names></string-name><string-name name-style="western"><surname>Bandla</surname><given-names>C.</given-names></string-name><string-name name-style="western"><surname>Garc&#237;a-Seisdedos</surname><given-names>D.</given-names></string-name><string-name name-style="western"><surname>Hewapathirana</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Kamatchinathan</surname><given-names>S.</given-names></string-name><etal>et al.</etal></person-group><year>2022</year><article-title>The PRIDE database resources in 2022: a hub for mass spectrometry-based proteomics evidences</article-title><source>Nucleic Acids Res.</source><volume>50</volume><fpage>D543</fpage><lpage>D552</lpage><pub-id pub-id-type="doi">10.1093/nar/gkab1038</pub-id><pub-id pub-id-type="pmid">34723319</pub-id><pub-id pub-id-type="pmcid">PMC8728295</pub-id></mixed-citation></ref><ref id="BCJ-2025-3431C60"><label>60</label><mixed-citation publication-type="journal"><person-group person-group-type="author"><string-name name-style="western"><surname>Okuda</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Watanabe</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Moriya</surname><given-names>Y.</given-names></string-name><string-name name-style="western"><surname>Kawano</surname><given-names>S.</given-names></string-name><string-name name-style="western"><surname>Yamamoto</surname><given-names>T.</given-names></string-name><string-name name-style="western"><surname>Matsumoto</surname><given-names>M.</given-names></string-name><etal>et al.</etal></person-group><year>2017</year><article-title>jPOSTrepo: an international standard data repository for proteomes</article-title><source>Nucleic Acids Res.</source><volume>45</volume><fpage>D1107</fpage><lpage>D1111</lpage><pub-id pub-id-type="doi">10.1093/nar/gkw1080</pub-id><pub-id pub-id-type="pmid">27899654</pub-id><pub-id pub-id-type="pmcid">PMC5210561</pub-id></mixed-citation></ref></ref-list></back></article></pmc-articleset>